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Abstract

Acute Lung Injury (ALI) is a set of signs and symptoms that lead to acute hypoxemic
respiratory failure characterized by bilateral pulmonary infiltrates not attributed to
cardiogenic origin. It is caused by a massive innate immune response, with the
migration of white blood cells (neutrophils and macrophages principally) and a cytokine
storm, followed by alterations in mitochondrial function, increase in reactive oxygen
species production, and oxidative stress that in turn induces more mitochondrial
damage. Several studies have shown that mitochondrial alterations are key events in
the mechanism of ALI and reducing mitochondrial dysfunction could be a possible target
in the treatment of the disease. Some investigators have determined that BMI1 has a
role in mitochondrial function, but its role is unclear, and the metabolic pathway through
which BMI1 regulates mitochondrial function and oxidative stress has not been
established. This study shows that BMI1 plays a pivotal role in mitochondrial function
during hyperoxia-induced ALI (HALI) in vitro and in vivo, and BMI1 silencing, or
depletion induces mitophagy and reduces cell survival by blocking the PI3K pathway
mediated by PTEN increases, decreasing the ability of lung cells to produce ATP and to
consume oxygen, resulting in the use of glycolysis as an energy source. In vivo, the
depletion of BMI1 decreases lung compliance, increases elastance, and induces
deleterious lung damage in mice, leading to worsening of HALI. This research describes
BMI1 as a possible therapeutic target in treating of ALI/ARDS.

x

Chapter 1: Introduction

Respiratory System and Lung
Historical perspective of lung study
Since time immemorial, human beings have tried to explain what they do not
know. To elucidate questions, there was a reliance on theology, religion, philosophy, art,
and science. The study of lung structure and function began with explanations about
breathing given by the philosopher Anaximenes (570-515 BC), the mathematician
Pythagoras (c.570-495 BC), and Hippocrates of Kos (460-370 BC), the father of clinical
medicine and the first known thoracic surgeon and pneumologist (1, 2). In the
Hellenistic period, Plato (427 – 348 BC) and Aristotle (384-322 BC) tried to provide a
deeper explanation but it was Erasistratus (330–255 BC) who first described a systemic
flow of air (pneuma) and blood (3). Later, Galen (129-. C216 AD) described the first
heart-lung interaction and his view of an open-ended vascular system. He postulated
that “part of the venous blood from the right ventricle flows through small
interventricular pores into the left ventricle. From there, warm blood is expulsed
to the arteries and dispersed throughout the body” (3). For centuries, Galen’s
description was accepted until the rise of the Renaissance in the the15th century when
physicians, anatomists, biologists, artists, etc., focused on live human anatomy. During
this period, Leonardo Da Vinci studied pulmonary and bronchial circulation and he drew
the anatomy of the lungs and diaphragm, without a complete understanding of the

complex process of respiration (Fig 1A) (2, 4-7). William Harvey (1578-1657 AD)
described the closed cardiovascular system and the nature of respiration while Marcello
Malpighi (1628-1694) confirmed this using microscopical studies of the structure of
capillaries and alveoli (Fig 1B) (3, 6, 8, 9). Later in the 18th century, Joseph Priestley
(1733-1804) and Antoine Laurent Lavoisier (1743-1794) explained the role of oxygen,
carbon dioxide, and nitrogen. However, in the 19th century, a clear explanation about
the importance of pressure-volume, thoracic cage, and muscle in lung function was
given by John Hutchinson (1811-1861), the inventor of the water spirometer, Guillaume
Duchenne (1806-1875) and Arthur Keith (1866-1955) (2).

A

B

i

ii

Figure 1.1. Lung anatomy descriptions. A. Leonardo da Vinci’s drawings, mirror-image (taken from
https://www.rct.uk/collection/919054/recto-the-bladder-verso-the-lungs). B. Malpighi’s drawing of the
pulmonary capillaries and alveoli. I: lungs with the alveoli on the left and the capillaries on the right. Ii:
pulmonary capillaries in a diagram of an alveolus that has been opened (taken from West, 2013 (10))
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In the 20th century before World War II, Fritz Rohrer (1888-1926) and Karl Wirz
(1896-1978) studied the mechanisms of respiration, airflow, volume, pleural pressure,
and lung expansion. Wirz together with Kurt von Neergaard (1887-1947), described
lung resistance and elasticity; the latter was the first in suggesting the important role of
surface tension in lung physiology; then in 1955, Richard E. Pattle (1918-1980) was
able to measure surface tension in animal lungs and described lung surfactant (11, 12).
In the second half of the 20th century, significant advances were made in the study of
lung physiology. The increase in technological resources, the detailed description of the
different respiratory diseases and the way to approach them, the advances in diagnostic
tests and therapeutics, and the progress of molecular medicine, have allowed the
understanding, validation, or retraction of previous knowledge in the field of
pneumology, with more than a million publications in the last 70 years (13, 14).

Lung Anatomy and Physiology
The respiratory process is carried out by several systems that collaborate with
the respiratory system to supply oxygen to all organs and tissues and remove waste
gases (15). The respiratory system has two components; the upper airway, also known
as the upper respiratory tract, is formed by the mouth and nasal cavity, pharynx, and
larynx, and the lower airway, or lower respiratory tract, is formed by the trachea,
bronchi, and lungs (16). These airways mobilize oxygen from the air with the help of the
thoracic cage and the diaphragm. Gas exchange occurs in the alveolar-capillary barrier
(ACB). The arteries of the circulatory system transport the oxygenated blood from the
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lungs to the organs. The veins move the blood rich in carbon dioxide back to the lungs
(17).
The process of respiration has three components. 1. Ventilation is the event by
which the air is inspired (due to the negative pressure created inside of the lungs by the
expansion of the thoracic cage) and expired (after the intrapulmonary pressure equals
and exceeds atmospheric pressure, and the thoracic cage exerts positive pressure to
push air out of the lungs). 2. Diffusion consists of two parts: external respiration is the
process by which the gas is exchanged in the alveolar-capillary barrier and internal
respiration is the gas exchange between the cells and the blood. 3. Perfusion is the
process whereby blood flows through vessels within the tissue and there is an
interchange of gases (oxygen and carbon dioxide) and other molecules across
semipermeable microvessel walls (18).
The lungs are the main organs in this respiratory process and play a crucial role
in gas exchange (17, 19, 20). This function is possible due to the maintenance of the
lung architecture, the fractal nature of the conducting airways (trachea, bronchial tree
(primary, secondary and tertiary bronchi), and bronchioles), and a large surface shaped
by the alveolar sacs formed by alveoli lined by alveolar epithelia (externally covered by
the basement membrane) and surrounded by the network of capillaries that form the
alveolar-capillary barrier (17, 21-23).

Alveolar Epithelium
Lung epithelial cells are an essential part of pulmonary function, and the alveolar
epithelium is composed of various cell types and represents more than 95% of the lung’s
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surface area (20). The lung surface area can vary according to the state of respiratory
health, on average, the surface could reach a mean of 70m2 (approximately 1m2 for each
kg of body weight) (24). The alveolar epithelium consists of type I and II pneumocytes
with different features and functions. Pneumocytes type I or type I alveolar epithelial cells
(AECI) are responsible for gas exchange, and pneumocytes type II or type II alveolar
epithelial cells (AECII) produce lung surfactant and antimicrobial factors (25).
AECI are branched and flat large cells (squamous). AECI only account for 20-40%
of the alveolar epithelia, they occupy 95% of the lung surface (20, 26-28). To ease gas
exchange, human pneumocytes type 1 can reach 5
̴ 000μm in apical surface and a ~0.2μm
of depth. AECI participate in regulating of surfactant secretion and alveolar fluid, and they
fuse with capillary endothelial cells to form the alveolar-capillary barrier. The oxygen in
the alveoli diffuses through the pulmonary surfactant that is lining the apical surface of
the alveolar epithelium until found AECI (28, 29). AECII are cuboidal cells with apical
microvilli and lamellar bodies (20, 28, 30). AECII, the most abundant cells in the alveoli,
represent 60-80% of the alveolar epithelium (10-15% of total lung cells), however it only
cover 2-5% of the lung’s surface. Regardless, AECII are vital for respiratory function,
producing, secreting, and up-taking pulmonary surfactants to avoid lung tissue collapse
and facilitating alveolar diffusion of gases, as well as regulating alveolar fluid (28, 30).
AECII contain 50% of the mitochondria within the lung and are necessary for epithelial
cell renewal and the production of cytokines and chemokines following lung injury (3036).
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Alveolar-Capillary Barrier (ACB)
The alveolar-capillary barrier is formed from the alveolar epithelial barrier and the
lung endothelial barrier (29). The alveolar epithelial barrier is composed of AECI and
AECII which are firmly joined by epithelial tight junctions regulating the flow of ions,
proteins, and fluids between the alveolar space and microvessels (29). Alveolar epithelial
cells fuse their basement membranes with the basal membrane of vascular endothelial
cells in a pseudo-structure called a respiratory membrane; the space between basal
membranes is the interstitium and in healthy conditions it is acellular. The increase in
respiratory membrane permeability and loss of ACB integrity induces lung damage and
disease (37, 38).

Acute Lung Injury (ALI) / Acute Respiratory Distress Syndrome (ARDS)
Acute lung injury (ALI) is a set of symptoms and signs that lead to acute hypoxemic
respiratory failure characterized by bilateral pulmonary infiltrates that are not attributed to
a disease of cardiogenic origin (39). It appears with the decrease in pulmonary
compliance, a measure of the distensibility capacity of the elastic pulmonary tissue to
expand and stretch and excessive inflammation (40, 41).

Historical perspective of ALI/ARDS study
In 1967, Ashbaugh and collaborators first described the adult presentation of
respiratory distress syndrome (RDS) after studying 12 patients with manifestations of
dyspnea, tachypnea, hypoxemia, and loss of compliance that did not respond to
respiratory therapy (42, 43). They found that this disease had a similar presentation to
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the neonatal/infant respiratory distress syndrome, and it could manifest with congestive
atelectasis and postperfusion lung (42). The authors proposed treatment with positive
pressure to avoid atelectasis, (atelectasis suggest surfactant dysfunction). They noted
the importance of the treatment with corticosteroids in patients with posttraumatic adult
RDS. Since then, multiple definitions of adult RDS were used until the term Acute
Respiratory Distress Syndrome (ARDS) was coined to describe patients with symptoms
and signs of acute respiratory distress (42, 43).
Murray and collaborators (1988), stratified the severity of lung injury (which
continues to be valid) and classified the severity of ARDS using a Lung Injury Score (LIS)
based on four parameters: 1. Diagnostic images (chest radiograph or CT scan); 2.
Hypoxemic score or oxygenation (the ratio of arterial partial pressure of oxygen (PaO2) to
fractional inspired oxygen (FiO2)); 3. Positive end-expiratory pressure (PEEP) and 4.
Static compliance of the respiratory system (44, 45). In 1994, almost 30 years after
Ashbaugh and colleagues described the syndrome, a panel of experts from the European
Society of Intensive Care Medicine, American Thoracic Society, and the Society of Critical
Care Medicine sought to redefine ARDS and created the Berlin definition (41, 46-49). The
Berlin consortium used the hypoxemic degree (the main functional and clinical
characteristic of ARDS) to establish three ARDS categories. Under normal conditions the
value of PaO2/FiO2 is around 500mmHg (47, 48, 50). The consensus defined ALI as the
mild category of ARDS with hypoxemic levels between 300mmHg ≥ PaO2/FiO2 >
200mmHg. The moderate presentation of ARDS has hypoxemic values of 200mmHg ≥
PaO2/FiO2 > 100mmHg and in severe cases the PaO2/FiO2 is ≤ 100mmHg (46, 47).
Another feature of this syndrome is the reduction in pulmonary artery wedge pressure
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(PAWP) to less than 18mmHg without pulmonary hypertension, thus excluding
cardiogenic origin as the cause of edema. Finally, the Berlin definition included the
presence of bilateral pulmonary infiltrates evident in the chest imaging as a major criterion
to define ARDS without making any differentiation between the severity of the
presentation (47-49). The most recent description of ARDS came in 2013 (51). It
corroborated the “timing of acute onset” of the disease as one week, as defined in the
Berlin consensus, it mentioned new therapeutics like gene therapy and mesenchymal
stem cells, and it suggested the need for a new definition for ARDS. Nevertheless, in the
interest of human health, the advent of new technology, new therapies, and new
challenges, e.g. SARS-CoV-2 virus infection, have led to a reevaluation of the previous
knowledge in lung research at the clinical and bench levels.

Epidemiology: Prevalence, incidence, morbidity and mortality
ALI is one of the major causes of morbidity and mortality in populations over 60
years old with poor survival (52). There are approximately 255,000 new cases per year
with high mortality (> 60%) that increases with time, worsening the disease and the
existence of comorbidities that puts a heavy cost burden on the US public healthcare
system (53-56). Patients with ARDS are susceptible to complications, long
hospitalization, and functional limitations, increasing the number of access to the
intensive care units (ICU) that can end in mechanical ventilation, both of which raise the
cost of care (57). To date, there is not any large international cohort study to determine
the overall epidemiology of ARDS (58). However, different studies have reported
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incidence, mortality, and the cost of medical treatment for specific countries or areas
(United Kingdom (54), United States (53)).
In a multicenter study, Bellani and colleagues (2016) analyzed data from patients
admitted to the ICU in a time frame of 28 days, from hospitals in 50 countries (58). In
the initial 48 hours of acute hypoxemic respiratory failure, 2377 patients developed
ARDS. Of the 2377 patients, 713 (30%) had mild presentation (ALI), 1108 (46.6%)
moderate, and 556 (23.4%) severe ARDS. Bellani et al., found an ARDS prevalence of
10.4% of the total patients admitted to an ICU. The incidence varied depending on
geographic location (cases/ICU bed per 4 weeks): Oceania, 0.57; Europe, 0.48; North
America,0.46; Africa, 0.32; South America, 0.31; Asia, 0.27. The mortality in this study
was 34.9% for patients with ALI, 40.3% for those with moderate ARDS, and 46.1% for
patients with severe ARDS (58).
Due to an underdiagnosis of 39.8% for ARDS, the lack of knowledge of the total
population served per ICU, the lack of accurate data from patients with ARDS that
require/do not require ICU care, and the lack of studies or data analysis that cover long
periods, the true incidence and prevalence of ARDS is likely underestimated (58).
The cost of the disease in survivors two years after the initial diagnosis is around
$35,000 per patient per year, leading to a total cost of 8 billion dollars per year to treat
new patients in the US (53). The economic burden, prevalence and incidence, morbidity
and mortality produced of the disease itself and its concomitant diseases are important
reasons why there is a need to understand the molecular basis and explore possible
treatment strategies for ALI/ARDS (53, 54).
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Etiology and Risk Factors
The origin of ALI/ARDS can be heterogeneous depending on etiology and risk
factors. According to the insult that triggers the inflammatory response, the etiology can
be classified into two groups: 1. Pulmonary ARDS (ARDSp), also known as local or direct,
and 2. Extra-pulmonary ARDS (ARDSexp), commonly known as systemic or indirect
(Table 1.1). Risk factors depend on several variables that predispose one to the disease
such as the age of presentation, genetic background, medical history, occupation, etc.
(Table 1.2). Clinically it can be difficult to differentiate the origin of the disease; however,
determining the moment of onset and progression is important for disease management.
The evolution of the disease depends on the origin, the recognition and opportune
diagnosis, the treatment, and the aggravating factors (55, 59, 60).
Table 1.1 Etiology of ALI/ARDS. Acute lung injury causes are classified into two groups depending on
the place where the inflammatory response is generated. Pulmonary (local – direct – primary), or Extrapulmonary (systemic – indirect – secondary). Modified from Aranda-Valderrama et al., (2017) and
Rezoagli et al., 2017
Pulmonary
•

•
•
•
•
•
•
•
•
•
•

Extra-pulmonary

Pneumonia
▪
Bacteria (i.e., Staphylococcus aureus)
▪
Virus (i.e., SARS CoV-2, Influenza sp.)
▪
Fungi (i.e., Pneumocystis jirovecii)
▪
Parasites (i.e., Toxoplasma gondii)
Sepsis
Inhalation injury (smoke, gases)
Ischemia-reperfusion
Aspiration of gastric content
Non-protective ventilation (i.e., VILI)
Lung contusion/trauma
Lung surgery (lung transplantation, lobectomy)
Drowning
Pulmonary vasculitis
Pulmonary embolism (blood cloth, fat, air, amniotic
fluid)

•
•
•
•
•
•
•
•
•
•

Blood transfusions (i.e., TRALI)
Non-pulmonary sepsis
Burns
Drug reaction (i.e., amiodarone)
Drug overdose
Trauma
Thoracic surgery (i.e., cardio-pulmonary bypass,
mastectomy, heart surgery, etc.)
Cancer treatment Radiotherapy/chemotherapy
Pancreatitis
Non-cardiogenic shock

The most frequent causes of ALI are pneumonia and sepsis (sepsis-related acute
lung injury), while risk factors such as age and its comorbidities, non-Caucasian ethnicity,
being male, coronary artery disease, smoking, alcohol abuse, other previous pulmonary
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diseases, and genetic polymorphisms, are related to disease progression and severity
(55). “Second injury” phenomenon or “second hit” has been proposed to explain the
worsening of the disease in some patients; this hypothesis has been studied in several
animal models (primates, pigs, rabbits, rats, mice) to find a therapeutic alternative in the
management of ALI/ARDS (61-64).

Acute Lung Injury Physiopathology
As mentioned previously, the appearance of ALI requires a necessary insult that
generates an immune response (pulmonary or extra-pulmonary insult induces damage or
death of AEC). At the molecular level, ALI is characterized by the activation of previously
quiescent alveolar macrophages and the activation of an innate immune response that
triggers the release of cytokines such as TNFα, IL-1β, IL-6, IL-8 and IL-10, and
chemokines such as CCL2, inducing local inflammation (30, 56). This cytokine and
chemokine release is followed by 1. The influx of white blood cells and macrophages from
the bloodstream that migrate into alveolar spaces for diapedesis or endothelial injury
(increasing cytokine storm), 2. The increase of the interstitial space, 3. The loss of alveoli
architecture and 4. The loss of cell integrity (epithelial and endothelial) (Figure 1.2).
All the changes that occur with the progression of the disease generate
mitochondrial dysfunction of the AEC that increases reactive oxygen species (ROS)
production, promotes oxidative stress, and induces alterations in the electron transport
chain (ETC) (56, 65-67). These events culminate in epithelial cell death, thereby
increasing lung permeability, resulting in pulmonary edema and, eventually, ALI (Figure
1.3).
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Table 1.2 Predisposing factors for developing ALI/ARDS
Intrinsic Factors
Extrinsic factors
• Individual
• Comorbidities
▪ Age (older than 60 years)
▪ Coronary artery disease
▪ Race (African American and Hispanic)
▪ History of smoking
▪ Gender (male)
▪ Sepsis
▪ Trauma and shock
▪ Vasculitis
• Genetic
▪ Contusion
▪ Genes
▪ Acute pancreatitis
▪ Polymorphisms and mutations [ABO group,
▪ Chronic alcohol abuse
Angiotensin Converting Enzyme (ACE)]
▪ Traumatic Brain Injury (TBI)
▪ Chromosomal
▪ Transfusion-associated lung injury (TRALI)
▪ Copy number variations (CVN)
▪ Diabetes
▪ Ventilator-Induced Lung Injury (VILI)
• Anatomic
▪ Congenital anomalies (alterations in embryogenesis) • Environmental
▪ Structural defects (birth or de novo)
▪ Burn
▪ Inhalational injury (smoke, noxious gases)
▪ Medications (opioids, salicylates, amiodarone,
▪
▪

tocolytics, chemotherapy)
Thoracic irradiation
Smoking

Healthy

Acute Lung Injury

Bronchiolar
epithelium
Sloughing of
bronchial
epithelium

Pulmonary
surfactant
AEC
I

Necrotic or
apoptotic
AECI

Interstitiu
m

AECI

Alveolar
macrophage

Increased
interstitial
space

Blood
vessel

Intra-alveolar
infiltrate (edema)

Activated
neutrophil

Activated Alveolar
macrophage

Vascular
endotheliu
m

Cytokines

Injured
AECII

Hyaline
membrane

Migrating
neutrophil

Fibroblast

Figure 1.2. Illustration of healthy vs injured alveoli after ALI/ARDS. The left panel shows a
healthy and intact alveolar-capillary barrier composed of the alveolar epithelium [alveolar epithelial cell type
I (AECI), alveolar epithelial cell type II (AECII)], interstitium, and vascular endothelium. The right panel
represents an alveolus after injury and disruption of the alveolar-capillary barrier, migration of neutrophils
from the bloodstream, activation of macrophages, cytokine storm, alveolar edema, and cell death.
Illustrated by artist Giovanny López-Mesa.
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Both epithelial cell integrity and mitochondrial function are crucial in normal lung
physiology. As the severity of the disease increases, the cellularity (determined by a large
number of neutrophils and macrophages) inside of the alveolar space increases as well,
and the integrity of the alveolar-capillary barrier is compromised, gas exchange and the
assimilation of oxygen within alveoli decreases, and the demand for supplemental oxygen
is higher. This results in hyperoxia-induced acute lung injury (HALI) (35, 68-73).

Figure 1.3 Physiopathology of ALI/ARDS.
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The diagnosis and treatment of ALI/ARDS according to the Berlin criteria is
based on time, oxygenation level, positive end-respiratory pressure (PEEP), chest
imaging, and origin of edema (74, 75). 1. The time of onset of the disease must be
within one week after known clinical insult or worsening of respiratory symptoms; 2. The
patient’s oxygenation determines the severity of the disease in mild (300mmHg ≥
PaO2/FiO2 > 200mmHg), moderate (200mmHg ≥ PaO2/FiO2 > 100mmHg) or severe
(PaO2/FiO2 ≤ 100mmHg); 3. A PEEP value minimum of 5 cmH2O is required for invasive
mechanical ventilation; 4. Chest imaging (radiographs or CT) with evidence of bilateral
infiltrates (opacities) not fully explained by lung/lobar collapse, effusions or nodules
(Figure 1.4 shows the comparison between radiographic of healthy and ARDS patients);
and 5. The respiratory failure and edema are not attributed to cardiac failure or
overload. Nevertheless, in the Kigali modifications of the Berlin definition of ARDS,
these criteria were adjusted based on the challenges in resource-poor settings (74),
Changed criteria included the removal of PEEP and a change to hypoxemia
measurement using the ratio of arterial oxygen saturation measured by pulse oximetry
(SpO2)/inspiratory oxygen fraction (FiO2) ⩽315 with SpO2 ⩽97%. To evaluate chest
opacities, chest ultrasonography and chest radiographs were considered when
available.

ALI/ARDS Treatment
The initial treatment of ALI/ARDS is established in two lines of I:1. Etiology and
progression of the disease in which the Lung Injury Prediction Score (LIPS) plays an
important role in minimizing iatrogenic injury; and 2. Symptoms and signs: values of
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PaO2/FiO2 (diagnostic criteria for severity), images, and time of instauration (76). The
etiology of the disease must be addressed to eliminate or reduce the damage caused
by the injurious agent. This may require antibiotic, antiviral, antifungal, or antiparasitic
therapy (when the cause is infectious), surgery in cases of primary or secondary
trauma, or pharmacological management for other pulmonary or extrapulmonary
causes.

A

B

Figure 1.4 Diagnostic imaging. Radiographs from: A. healthy patient (left), and B. ARDS patient (right).
Courtesy of Camila Ardila Sabogal, M.D. Internal Medicine Director, San Juan de Dios Hospital Puerto
Carreño -Vichada-Colombia. Hospital Universitario Nacional de Colombia.

The guidelines for the management of the disease were written by the Joint
Standards Committee of the Faculty of Intensive Care Medicine and the Intensive Care
Society (ICS), using GRADE methodology. ALI/ARDS is an inflammatory disease with
increased respiratory distress. The first line of management points to the treatment of
dyspnea to improve respiratory quality and to the pharmacological treatment of
inflammation. Clinical treatment with oxygen therapy is mandatory in ARDS and the
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method of administration depends on the severity, and clinical evolution (Figure 1.5).
GRADE recommendations are strongly in favor of protective ventilation: tidal volume
(Vt), high PEEP (moderate and severe ARDS), neuromuscular blocking agents (NMBA),
and prone positioning, while high-frequency oscillation ventilation (HFOV) and
recruitment maneuvers are contraindicated (76, 77). The GRADE recommendations for
other lines of treatment such as ECMO (extracorporeal membrane oxygenation) and
conservative fluid management are variable. Corticosteroid use, ECCO2R
(extracorporeal carbon dioxide removal), and inhaled vasodilators (iVasoD) are still
controversial depending on the research source. Glucocorticoids, for example, may not
be effective but can lead to neurological and gastrointestinal complications, concomitant
infections, immune suppression, and other side effects (76, 77). Trials using
pharmacological therapies with acetylsalicylic acid, antioxidants, beta-2 adrenergic
agents and keratinocyte growth factor have failed in reducing the incidence of ARDS
(78). Effective therapy for the treatment of ALI/ARDS is still unknown and its
management is guided by supportive care.

Oxygen Therapy and Hyperoxia Induced Acute Lung Injury (HALI)
Oxygen Therapy
Supplemental oxygen treatment is the most used therapy to manage hypoxemia.
Oxygen is administered to the patient with various devices that differ in their invasiveness.
Noninvasive ventilation (NIV) methods can include fixed performance devices to deliver
constant FiO2, e.g. Venturi mask system or variable performance devices to deliver
variable FiO2, e.g. nasal cannula, simple face mask, non-rebreather reservoirs mask, high
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flow nasal oxygen cannula (HFNC) versus invasive ventilation methods or endotracheal
mechanical ventilation (79, 80). Oxygen therapy is a common medical treatment, and it
has been widely used not only to treat lung diseases with hypoxemic respiratory failure
but also to treat ischemic pathologies such as acute myocardial infarction and stroke, and
to manage other diseases independent of the normoxemia. Prolonged use of oxygen
could lead to hyperoxemia-induced toxicity in a dose-dependent manner (81).
ALI/ARDS treatment requires oxygen therapy due to decreased oxygen levels and
the loss of the AECI ability to carry out gas exchange; with the progression of the disease,
the pulmonary hypoxia turns into systemic hypoxemia (39). The oxygen deficit in several
organs could trigger systemic inflammatory response syndrome, reducing metabolic cell
rate and leading to multiple organ dysfunction syndrome; these complications increase
morbidity and mortality associated with ARDS (82-86).
All the pathophysiological features of ALI/ARDS at the macro and micro levels
(disruption of alveolar-capillary barrier, edema, massive inflammatory response,
mitochondrial damage, and concomitant cell death) reduce the gas exchange and
therefore the supply of oxygen to the entire body. The perpetuated damage increases
the oxygen demand, and the lungs remain unable to fulfill their respiratory function
creating a vicious cycle between high demand and high oxygen supply, with the risk of
inducing pulmonary oxygen toxicity (POT) and exacerbation of underlying lung injury
(87, 88).
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Figure 1.5 Algorithm for ARDS treatment. ARDS, acute respiratory distress syndrome; CPAP,
continuous positive airway pressure; HFOV, high-frequency oscillatory ventilation; FIO2, fraction of
inspired oxygen; PEEP, positive end-expiratory pressure; Pplat, pressure measured after a 0.5-second
end-inspiratory pause when there is no flow; SpO2, oxygen saturation as measured by pulse oximetry; VV
ECMO, venovenous extracorporeal membrane oxygen. (Taken from Fan et al., 2018)
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Hyperoxia-induced Acute Lung Injury (HALI)
Under normal conditions, the fraction inspired of O2 (FiO2) is 21%. This amount
can be adjusted up to 100% depending on the needs of the patient, the delivery device
used and the disease. In ALI/ARDS, oxygen therapy can increase FiO2 up to 50-100%
at 1 atm of pressure (79, 80).
The goal of oxygen therapy is to increase the oxygenation of tissues and organs
to meet their metabolic oxygen demand; however, even high FiO2 with positive pressure
does not guarantee that the tissue oxygen supply requirement will be met. Despite the
constant use of oxygen in the care of critically ill patients, it is not an innocuous agent,
its use has physiological and biochemical implications. Long-term oxygen therapy at
normal or high pressures, induces cellular toxicity due to cellular hyperoxia, increasing
the production of free radicals, reactive oxygen species, and partially reduced oxygen
metabolites (87-89). When hyperoxia induces POT, it becomes a nosological entity
known as hyperoxia-induced acute lung injury (HALI) (90-92).
HALI is characterized (similar to other forms of ALI) by innate immune response,
polymorphonuclear (PMN) cell migration, cytokine storm, pulmonary permeability, and
death of epithelial lung cells and vascular endothelium; if the injury (excess oxygen)
persists, HALI can lead to ARDS (93, 94). Lung cells exposed to hyperoxia demonstrate
increased ROS production and oxidative stress and activate promoters of inflammation
such as mitogen-activated kinases (MAPKs), c-Jun N-terminal kinase (JNK),
extracellular signal-regulated kinase (ERK), and NF-κB. Meanwhile, ROS activate the
p38 pathway, related to cell death by apoptosis and necrosis via caspases/Bak/Bax
producing mitochondrial damage or regulating apoptosis via the Bcl2 family (92-94).
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Inflammation, mitochondrial damage, and cell death trigger the activation of
alveolar macrophages (generating more inflammatory cytokines), PMN recruitment, loss
of alveolar-capillary barrier, an increase of interstitium and formation of hyaline
membrane; all of these are ALI pathophysiological characteristics (Figures 1.2 and 1.3).
If the patient survives, he/she will never have 100% recovery; hypoxemia, restricted
lung capacity and in the worst case, lung fibrosis, may all continue (95). Many
researchers have studied the molecular mechanism of HALI to establish adequate
treatment; however, satisfactory results have not yet been reached and the search for
suitable therapeutic targets continues.

Models to study ALI/ARDS
The first studies of ALI/ARDS were completed in postmortem patients, posttransplant surgical lung explants, and lung biopsies (95). The pathological study
approach is a challenge for pulmonary diseases due to their complexity; the most
frequent way to establish management guidelines in pulmonary patients are through the
use of diagnostic imaging, blood markers, functional tests, and medical record review.
In vitro and in vivo models seem to be the best way to study this pathology even though
there are differences between animal and human presentations of ALI (34, 93, 96, 97).
In vitro modeling is based on the study of mammalian epithelial and endothelial cells to
assess the physiological and molecular mechanisms of the disease (93).
Due to the complexity of ARDS, the multiple pathways involved in the
development of the disease, and the pathophysiological characteristics, it is necessary
to establish animal models (in vivo models) for its study (34, 95-97). Nevertheless, the
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perfect model does not exist and the approach to the study of the disease depends on
the pathological feature, the type of injury to mimic and the experimental question to be
answered (98). To replicate the human hallmarks of the disease, researchers suggest
the use of large mammals, including primates, pigs, dogs, or sheep, however there are
concerns with cost, ethics, and time (64); small mammals, e.g. rabbits, rats, or mice are
more accessible models, easier to genetically modify, reliable, less costly and with the
ability to generate results in shorter time frames. However, the biggest challenges have
been to define ALI/ARDS in an animal model and how to provide critical care (34, 95,
96).
Matute-Bello et al. (2008) reviewed ALI animal models highlighting differences
and similarities with the human presentation of the disease; they compared the type of
insult that induces ALI i.e., sepsis (simulated by lipopolysaccharide (LPS), intravenous
and intrapulmonary bacteria, peritonitis, cecal ligation and puncture), trauma, ischemiareperfusion, aspiration of gastric contents (similar to acid aspiration), fat embolism (with
oleic acid) and hyperoxia. They provided a comprehensive summary of the principal
animal models to study the disease and concluded that is difficult to use a unique
technique due to the size of the animal, the interaction between etiologies, risk factors,
and comorbidities associated with ALI/ARDS, and the unique characteristics of different
animal species (97). Matute-Bello et al. (2011) then published workshop proceedings
describing “very relevant criteria in standard models of ALI”: 1. Histological evidence of
tissue injury, 2. Alteration of the alveolar-capillary barrier, 3. Inflammation, 4.
Physiological dysfunction (34).
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Hyperoxia animal models are used to produce direct injury with a high partial
pressure of oxygen; this is a good model for studying ALI/ARDS because of its reliability
and replicability. This model mimics the acute phase of ARDS with PMN infiltration,
epithelial lung injury, AECII proliferation and scarring, and mitochondrial dysfunction.
(34). The damage is related to the oxygen dose (especially FiO2 >90%), the time of
exposure, and the PaO2 (99). Due to the characteristics explained above, the work
described in this research study will use hyperoxia to induce cell damage in vitro and
the HALI model for the in vivo section.

Mitochondria
The endosymbiotic theory holds that mitochondria, intracellular organelles,
originated from the endosymbiosis of Alphaproteobacteria which lost genetic information
during evolution (100-102). Mitochondria are key organelles in eukaryotic cells,
maternally inherited and their proteins are encoded in the nuclear and mitochondrial
genomes. In humans, mitochondria have approximately 1500 proteins with multiple
functions; they are involved in different cellular processes such as energy production,
inflammation, fatty acid biosynthesis, cell growth, buffering intracellular calcium, oxygen
sensing, innate immunity, autophagy, redox signaling, stem cell reprogramming,
activation of endoplasmic reticulum (ER)-stress response, apoptosis and heme synthesis
(103-108). Mitochondria produce energy or adenosine triphosphate (ATP) for cellular
metabolism by oxidative phosphorylation (OXPHOS) and the tricarboxylic acid cycle
(TCA), which is why they are considered the “powerhouses” of the cell (100, 106, 109,
110); this process generates about 90% of ROS and its alterations are related to the most
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common inborn errors of metabolism (110). Mitochondrial alterations have been
associated with neurodegenerative diseases, cancer, aging, and other multisystemic
pathologies (107, 111, 112).
Mitochondria are formed by two phospholipidic membranes, with different lipid
compositions, features, and functions of transmembrane proteins; the outer mitochondrial
membrane (OMM) which resembles the eukaryotic cell membrane, provides the external
structure of the organelle and is in contact with the cytosol. The inner mitochondrial
membrane (IMM) is similar to bacterial membranes since it invaginates into the
mitochondrial matrix forming the cristae and has a high protein/lipid ratio. The OXPHOS
machinery (electron transport chain complexes) lies within the IMM; the compartment
between the inner and outer membrane is the intermembrane space (IMS). Mitochondrial
membranes have different permeabilities. The OMM permits the flux of small molecules
and ions through voltage-dependent anion channels (VDACs); the IMM is permeable to
carbon dioxide (CO2), oxygen (O2) and water. Most of the proteins in the mitochondrial
proteome are transported from the cytosol to the organelle according to the mitochondrial
targeting sequence (MTS); those proteins or their precursors can be anchored in the
OMM, enter the IMS or be translocated to the IMM and matrix to be modified and
stabilized (100, 113-115). Phospholipid composition of the IMM creates an
electrochemical gradient due to the transport of electrons generating the mitochondrial
membrane potential Δψ that is an indicator of the mitochondrial functionality (116).
Mitochondrial function and structure change to maintain their health or to respond
to cellular metabolic needs; these processes are known as mitochondrial dynamics and
consist of fission (the fragmentation of one organelle into two or more, generally aimed
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at eliminating the altered or dysfunctional portion), fusion (the joining of two or more
organelles into one), transport and mitophagy (degradation of mitochondria through
autophagy) (106, 108, 112, 117). The balance between fusion and fission processes is
required to maintain mitochondrial integrity, cell survival and stability; the fission event
of mitochondrial dynamics is regulated by Dynamin-related/-like protein 1 (Drp1), via
interaction with fission protein 1 (Fis1) and mitochondrial fission factor (Mff). The fusion
process is regulated by 24itofusin 1 and 2 (Mfn1 and Mfn2) ensuring OMM fusion, and
mitochondrial dynamin like GTPase OPA1 is responsible for IMM fusion. Impaired
mitochondria cleaved in the fission process are labeled by ubiquitination to enter
mitophagy. Prevalence of mitochondrial fission is an indicator of mitochondrial
dysfunction, mitochondrial membrane depolarization, respiratory chain alterations,
mitochondrial DNA (mtDNA) fragmentation, leading to increased ROS production and
oxidative stress which can trigger apoptosis (111) (Figure 1.6). Imbalances in
mitochondrial dynamics are characteristics found in several human pathologies such as
non-small cell lung adenocarcinoma, pulmonary hypertension, heritable juvenile
parkinsonism, Charcot-Marie-Tooth disease 2A, cardiometabolic diseases, amyotrophic
lateral sclerosis (ALS), Huntington’s Disease, Patent ductus arteriosus, Alzheimer’s
Disease, etc. (118).
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Figure 1.6 Mitochondrial dynamics and mitochondrial dynamic proteins

Relevance of Mitochondria in ALI/ARDS
Maintaining mitochondrial health and its bioenergetic balance is necessary for ALI
treatment for which different studies have been completed in animals, mainly using the
mouse model of lipopolysaccharide-induced acute lung injury (LALI) (66, 103, 119).
Today, research points towards translational studies using mitochondrial therapy to
improve human health (120-122). Preserving mitochondrial function is not only important
for the integrity of the lung but also necessary to successfully treat various diseases and
improve some conditions, such as inflammatory responses, manifested as skin wrinkles
and hair loss (123). New therapies target inherited or acquired mitochondrial diseases
and other pathological conditions where mitochondrial metabolism and biogenesis are
compromised, or there is increased mitophagy (124-130). Some of these targets are still
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being evaluated using in vivo models (mouse, zebrafish, Drosophila, and non-human
primates), in vitro models and clinical trials (129). A few proposed treatments include the
use of vitamins and cofactors, antioxidants, mitochondrial gene therapy, mitochondrial
transplantation (replacement therapy), regulation of mitochondrial dynamics, bypassing
of the mitochondrial genome, activation of mitochondrial biogenesis, and regulation of
mitophagy (120, 121, 125, 127, 129, 131).
The relevance of mitochondria in ALI/ARDS has been studied previously, i.e.,
Islam and colleagues, (2012) demonstrated how healthy mitochondria from cultured bone
marrow-derived stromal cells (BMSCs) (instilled into the lungs), can migrate in vesicles
from BMSCs to the injured epithelial cells to restore the damage and protect against the
injury (66, 67). Similar results were obtained for macrophages in alveoli; in this case, the
mitochondria move from mesenchymal stromal cells through tunneling nanotube (TNT)like structures, enhancing the phagocytic activity of macrophages. Regulators of
mitochondrial dynamics, fusion and fission proteins and mitophagy play a crucial role in
ALI. Bcl-2 (B-cell lymphoma 2), an anti-apoptotic regulator acts in mediating the protective
effect of IL-6 by regulating Bcl-2 family member interactions (73). Bcl-2 modulates the
translocation of Parkin from the cytoplasm into the mitochondria regulating mitophagy
mediated by PINK1/Parkin (119).

BMI1 B lymphoma Moloney murine leukemia virus insertion region 1 homolog
BMI1 (B cell-specific Moloney murine leukemia virus integration site 1), is a protooncogene and a member of the Polycomb Repressive Complex 1 (PCR1). It is a
ubiquitous protein widely studied for its multiple functions in cell cycle regulation, cell
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homeostasis (maintaining a balance between proliferation and senescence), stem cell
renewal, chromatin acetylation, development, and the DNA damage response (DDR)
pathway (132). BMI1 is overexpressed in some types of cancer and more recently has
been found to be involved in mitochondrial metabolism (133, 134).

Structure of Protein
The BMI1 gene is located on chromosome 10 in humans (10p12.2) and
chromosome 2 A3 in mice; the gene encodes for a 37kDa protein with 326 amino acids.
The similarity between human and mouse protein is 98% and 92.4% at the cDNA level
(133, 135). BMI1 protein is formed by three functional regions (Figure 1.7): 1. The Nterminal end has a RING finger domain necessary for DNA strand break binding (crucial
for its role in DDR) and it is the site of binding with RING1A/B proteins to form the E3
ubiquitin ligase complex of PCR1 (133) (Figure 1.7 B), 2. The central domain is a helixturn-helix (HTH) domain, recently defined as a ubiquitin-like domain (UBL) called
RAWUL (RING finger and WD-40 associated ubiquitin like) domain; it interacts with
polyhomeotic proteins (PHC1, PHC2, PHC3) and 27itofusi group (PcG) proteins,
transcription factors (E4F1, Zfp277) and it is involved in BMI1 binding with DNA (Figure
1.7 C):, 3. The carboxyl-terminal end has a PEST-like domain; this is a domain rich in
proline (P), glutamic acid I, serine (S) and threonine (T) that acts as a proteolytic signal
and for cell proliferation. BMI1 protein has two nuclear localization signals: NLS1 and
NLS2, of which NLS2 is active for nuclear localization (133, 135, 136) (Figure 1.7)
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Figure 1.7 Structure of BMI1 protein. A. Illustration of full-length BMI1 protein structure. Main domains
are represented with their relative size and amino acid location, RING (really interesting new gene); NLS
(nuclear location signal); HTH (helix-turn-helix) or RAWUL (RING finger and WD-40 associated ubiquitin
like); PEST (domain rich in proline, glutamic acid, serine, and threonine). B. Crystal structure of the BMI1RING1B core domain complex required for the efficient ubiquitin transfer. Here, the N-terminal RING /Ubox domain of BMI1 (residues 5-101, blue structure) is co-crystallized with the N-terminal domain of the
RING finger protein RING1B (residues 15-114, red structure) (PDB ID: 2H0D; PMID: 16714294). C. the
fusion protein containing PHC230–64 fragment fused to the N-terminus of the central BMI1 UBL domain
(residues 130-231) presented in rainbow color, where N- and C-terminal regions are shown in blue and red
colors, respectively (PDB ID: 2NA1; PMID: 27827373).

BMI1 in Mitochondria
In global BMI1 knockout mice, decreased expression is associated with increased
production of mitochondrial ROS, alterations in the ETC, and activation of the DNA
Damage Response pathway (DDR) (133, 134, 137, 138). The mechanism by which this
occurs is not yet elucidated. BMI1 is necessary to renew lung stem cells and repair lung
tissue following lung injury and oxidative stress; however, the consequences of the lack
of a normal expression of BMI1 in lung tissue remain unknown. Upregulated BMI1 is
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associated with the overexpression of PI3K, p-AKT (Protein Kinase B, phosphorylated at
Ser473), and mTOR (mammalian target of rapamycin), and with the inhibition of PTEN
(phosphatase and tensin homolog) causing cardiac dysfunction, cardiac fibrosis and
evidencing a regulatory activity of the PI3K/Akt-mTOR pathway (139). In addition, BMI1
is involved in the maintenance of hematopoietic function and autophagy-mediated
necroptosis (140, 141). This type of programmed cell death is related to mitophagy and
with changes in the expression of PINK1 (PTEN-induced kinase 1), Parkin, and DJ1
(Protein deglycase DJ1), all closely linked to the PI3K/Akt-mTOR signaling pathway and
alterations in TCA enzyme activity (103, 119, 142, 143). BMI1 expression decreases
under hyperoxic conditions and could be a potential mediator of the organ damage
associated with HALI, as previously demonstrated for cardiomyocytes and stem cells
(144-149).
Acute lung injury can appear at any age, but predominantly occurs over the age of
60. ALI has diverse etiologies and risk factors; it requires a harmful event that generates
damage to the pulmonary epithelium and vascular endothelium, triggering an immune
response, alveolar macrophage activation, release of inflammatory cytokines;
extravasation of neutrophils and lung infiltrates (150). Despite all the clinical and
experimental research completed, mortality and the cost burden caused by the disease
increase annually. The molecular mechanisms of ALI/ARDS have not yet been clarified;
there is no cure for this illness and the therapeutic alternatives are directed towards
management of hypoxemia with oxygen therapy, treatment of symptoms related to the
cause, or directly with the illness, and life support. Although supplementary oxygen is the
first line of treatment for ALI/ARDS, long-term oxygen therapy induces oxygen toxicity
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that in turn causes deleterious damage and exacerbates the severity of the disease.
Hyperoxia increases oxidative stress and induces acute lung injury and has been a
reliable model to study ALI/ARDS in vivo and in vitro.
Mitochondrial damage is a critical event in the progression of ALI. It can induce
energetic imbalance, mitophagy, and finally cell death; therefore, maintaining
mitochondrial health is a relevant milestone in the study and treatment of ALI. The
decreased expression of BMI1, a Polycomb group protein of the is related to oxidative
stress and mitochondrial damage, both characteristic events in acute lung injury;
interestingly hyperoxia reduces BMI1 expression. In this dissertation, I elucidate the
mitochondrial role of BMI1 in HALI with in vitro (cell culture) and in vivo (knock-out mouse)
models. My work shows that the decreased or absent expression of BMI1 induces an
increase in proteins involved in mitophagy, a decrease in respiratory and mitochondrial
enzymatic activity, and cell damage. Additionally, I present BMI1 as a possible therapeutic
target in treating the disease.
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Chapter 2: Pivotal Role of BMI1in ALI/ARDS in vitro model

Background
Acute Respiratory Distress Syndrome (ARDS) is characterized by the rapid onset
of respiratory distress (usually unresponsive to therapy), a decrease in lung compliance
and volumes, and a loss of the ability to regulate gas exchange and it can trigger a severe
respiratory failure (47, 49, 151). ARDS worsens with time and is characterized by
comorbidities such as hydrodynamic imbalance, cor pulmonale, lung infections,
atelectasis, pneumothorax, pulmonary embolism, and damage to other organs (152-154).
It mainly affects individuals over 60 years old with more than 250,000 new cases per year
in the US and at a high expense on the healthcare system (53-55, 154).
Lung epithelial cells play a critical role in ALI. Type I alveolar epithelial cells (AECI)
are responsible for gas exchange and type II alveolar epithelial cells (AECII) produce lung
surfactant and antimicrobial factors (25). Oxygen toxicity becomes evident with the
appearance of symptoms and signs after 24 hours of oxygen therapy with a FiO 2 ≥ 0.75;
the lung damage results in hyperoxia-induced acute lung injury (HALI) (35, 68-73, 90).
ALI is characterized by the activation of an innate immune response, an influx of
macrophages and white blood cells, and consequently, the release of cytokines and
chemokines into alveolar spaces (30, 56). This is followed by alterations in mitochondrial
function that increase reactive oxygen species (ROS), promote oxidative stress, induce
alterations in the electron transport chain (ETC), and in turn cause more mitochondrial
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dysfunction (56, 65-67). These events lead to epithelial cell death, thereby increasing lung
permeability. Ultimately, this culminates in pulmonary edema and eventually, ALI. Both
epithelial cell integrity and mitochondrial function are crucial in normal lung physiology.
Among the epithelial cell types, AECIIs are the most abundant cells in the alveoli (6080%) and comprise 10-15% of total lung cells. They are vital for respiratory function,
contain 50% of the mitochondria within the lung, and are necessary for appropriate lung
function (31-33).
Mitochondrial research uses different biomarkers, from proteins belonging to
structure and metabolism, to external regulators and recruiters that condition
mitochondrial function (67, 122). Polycomb complex protein BMI1 (B cell-specific Moloney
murine leukemia virus integration site 1), a ubiquitous protein widely studied for producing
chromatin acetylation and being overexpressed in some types of cancer, is also involved
in mitochondrial metabolism.

Materials and Methods
Cell culture
Three different lung cell types were grown in a humidified incubator and were
exposed to normoxic [O2 = 21%] and hyperoxic conditions [O2 > 90%] (in hyperoxia
chamber) for different time points (6-72h) to determine if the expression of BMI1 in lung
cells changes under hyperoxia conditions. 1. H441 lung epithelial cells; (this cell line
has features of AECII cells and Clara cells, HTB-174™; American Type Cellular Collection,
Rockville, MD), grown in RPMI 1640 medium supplemented with 10% FBS and 1%
antibiotic (penicillin-streptomycin)/antimycotic (amphotericin B) solution. H441 cells
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between passages 7-20 were used for all the experiments. 2. Human Lung
Microvascular Endothelial Cells (HMVEC-L) cultured in Microvascular Endothelial
Growth Medium BulletKit™ (EGM™-2 MV) prepared according to the manufacturer’s
protocol (Lonza, Walkersville, MD; Catalog #: CC-2527). The current study used HMVECL cells were between passages 4-10. 3. Small Airway Epithelial Cells (SAEC)
maintained in Small Airway Growth Medium BulletKit™ (SAGM™ SingleQuots™)
following the manufacturer’s instructions (Lonza, Walkersville, MD; Catalog #: CC-2547);
these cells were used between passages 4-10. All cells were grown in a humidified
incubator at 37°C and 5% CO2.
H441 epithelial cells, HMVEC-L and SAEC primary cells at ≈50-60% of confluency
were exposed to high oxygen concentration (>80%) for 6, 12, 24, 48, and 72 hours in a
hyperoxia (HO) chamber or 48 hours to normoxia (NO) (21% O 2). Further, cells were
washed with cold 1× PBS and trypsinized (Trypsin-EDTA 0.025%) for 5 min by incubating
at 37°C. Cells were then harvested completing 10 ml with cold 1× PBS by centrifuging at
1500 rpm for 5 min. The supernatant was discarded, and the pellet was re-suspended in
1 ml of cold PBS 1× and centrifuged again at 1500 rpm for 5 min. The resulting pellet was
stored at -80°C until further use.

BMI1 Silencing
H441 cells were grown in 100 mm precoated culture dishes until ≈60% of
confluency to silence BMI1 using small interfering ribonucleic acid (siRNA). H441 cells
with the desired confluency were transfected using siRNA from Dharmacon™ for BMI1
(sense sequence was 5’GAACAGAUUGGAUCGGAAA3’) and control (scrambled) siRNA
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(sense sequence was 5’GACUUCCGUCGACAUUAUU3’). The silencing was completed
in three replicates per treatment using Lipofectamine 2000 (Thermo Fisher Scientific, Inc.)
and BMI1 siRNA or control siRNA following manufacturer’s recommendations. A total of
four groups were used for all the experiments as follow: 1 Control siRNA normoxia =
normoxic conditions + scrambled siRNA (experiment control). 2 BMI1 siRNA normoxia =
normoxic conditions + BMI1 silencing (evaluates the effect of silencing BMI1 in normal
conditions of oxygen). 3 Control siRNA hyperoxia = hyperoxic conditions + scrambled
siRNA (evaluates the effect of injury -hyperoxia damage- in BMI1 expression). 4 BMI1
siRNA hyperoxia = hyperoxic conditions + BMI1 silencing (additive effect between the
injury and the genetic modification, it evaluates the effect of silencing BMI1 with hyperoxia
damage). After 18 hours, the medium was changed to RPMI-supplemented medium.
Non-silenced and BMI1-silenced cells were exposed to normoxic and hyperoxic
conditions for 48 hours in humidified incubator supplemented with 5% CO 2. After
incubation at normal and high oxygen levels, H441 cells were trypsinized, as described
in the cell culture methods for experiments with live cells (enzyme activity assays, life
mitochondria isolation, oxygen consumption rate) and the cells processed immediately.
For protein or RNA isolation, pellets were stored at -80°C until future use.

Protein isolation and western blot
1. Whole cell lysate (WCL)
WCL was prepared by adding 200 μl of protein isolation buffer (150 mM NaCl, 50
mM Tris, and 0.5% NP40, pH 7.4 supplemented with protease and phosphatase inhibitors
1:100) and thermic shock induced by thawing and freezing cells three times. The WCLs
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were sonicated for 5 minutes (pulses of 15 sec with intervals of 10sec) at 50% amplitude
in Qsonica Q700 sonicator. Next, the lysates were centrifuged for 15 minutes at 4°C ×
21000xg and the supernatant was collected in low binding protein tubes and stored at 80°C. Protein quantification was conducted using a BCA protein assay following
manufacturer’s recommendations (ThermoFisher Scientific, Inc #23225, Pierce,
Rockford, Waltham, MA).

2. Western blot analysis.
Protein expression levels were analyzed by loading 10 μg of whole cell lysate
(WCL) from BMI1-silenced and non-silenced cells exposed to NO and HO conditions on
10% SDS-PAGE or in gradient gels (4-20%) for separating the lower molecular weight
proteins. The proteins were transferred to PVDF membrane, blocked in 5% BSA in TBST
exposed to primary antibodies and incubated overnight at 4°C. Following washes, a
secondary antibody was added and incubated for 1 hour at room temperature on a
shaker. Membranes were washed and protein expression (bands) was visualized with
chemiluminescent Kwik quant ECL solution (Kindle Biosciences, Greenwich, CT), ECL or
Femto (Thermofisher Scientific, Inc #32209 and #34095, Pierce, Rockford, Waltham, MA)
(see Appendix 2. Table A1 for list of antibodies). The visualized proteins were quantified
using ImageJ (NIH, Bethesda, MD), and the ratio of protein to its loading control (β-actin)
was calculated using the ImageJ software. The results were saved to Excel. The silencing
experiments were performed independently several times during this study. The
representative western blot images are presented. The blots were quantified, and data
represents the mean ± SEM. N=3 per group.
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Live mitochondrial isolation and mitochondrial proteins
Live mitochondria were isolated from H441 cells with modifications to the protocol
described in Hartwig 2015 for lung cells (155). Live mitochondria were isolated in
homogenization buffer containing sucrose, EGTA, mannitol, DTT, NaCl, and KCl by ultracentrifugation in a sucrose gradient prepared in the homogenization buffer at
concentrations of 2, 1.5, and 1 M. The mitochondria were obtained from the middle layer
after several cold ultra-centrifugation steps (mitochondrial fraction). Mitochondria were
resuspended in the cell growth medium for the OCR experiment or in resuspension buffer
for protein isolation. Mitochondrial proteins were quantified with Pierce™ Detergent
Compatible Bradford Assay Reagent and then kept frozen at -80°C.

Reverse transcription quantitative polymerase chain reaction (RT-qPCR)
Total RNA was isolated from H441 cells (silenced and non-silenced for BMI1 and
exposed to NO and HO conditions) using Rneasy Mini Kit® from Qiagen (Germantown,
MD), purified with Rnase-free Dnase set (Qiagen), dissolved in Rnase-free water and
stored at -80°C. For reverse transcription PCR (RT-PCR), the iScript cDNA synthesis kit
(BioRad, Hercules, CA) was used following the manufacturer’s instructions and 1 μg of
total RNA was reverse transcribed. To determine relative expression levels of mRNA,
quantitative RT-PCR was performed using cDNAs and TaqMan qRT-PCR probes: BMI1
(Hs00995536_m1), β-ACTIN (Hs01060665_g1), TIMM23 (Hs00197056_m1), MFN1
(Hs00966851_m1),

MFN2

(Hs00208382_m1),

(Hs01552605_m1),

FIS1

(Hs00211420_m1),

OPA1
PTEN

(Hs01047013_m1),
(Hs02621230_s1),

DRP1
AKT

(Hs00178289_m1), PINK1 (Hs00260868_m1), PARKIN (Hs01038322_m1), DJ1
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(Hs00994893_g1),

NRF2

(Hs00975961_g1),

BCL2

(Hs00608023_m1),

and

NLRP3(Hs00918082_m1). The qRT-PCR was completed in a QuantStudio 3 PCR
System (Life Technologies) according to the manufacturer’s instructions for TaqMan
probes and TaqMan Fast Advanced Master Mix. Data was analyzed by ΔΔCt method
using β-actin (internal calibrator).

Measurement of oxygen consumption rate (OCR)
Oxygen consumption rates were determined using a Seahorse Xfe96 Analyzer
(Seahorse Biosciences, North Billerica, MA). Briefly, live H441 cells treated with
scrambled siRNA or silenced with BMI1 siRNA and exposed to NO and HO conditions
were plated at 30,000 cells/well in 50 μl of growth media. The 96-well plate was
centrifuged at 200×g 2 minutes without brake or acceleration speed and incubated in
humidified incubator with 5% CO2. After 1 h, growth medium was replaced with 180 μl of
RPMI1 Seahorse-Agilent medium pH 7.4 and supplemented with glucose, sodium
pyruvate and L-glutamine following manufacturer’s instructions. H441 cells were
incubated for 1 hour in a CO2 free incubator and the oxygen consumption rate (OCR) and
respiratory parameters were measured by the addition of ETC inhibitors [final
concentration

per

well:

oligomycin

1.0

μM,

carbonyl

cyanide-p-

trifluoromethoxyphenylhydrazone (FCCP) 0.5 μM and Rotenone/Antimycin-A 0.5 μM].
For live mitochondria derived from H441 cells, mitochondria were isolated as previously
described, an aliquot was stained with Mito Tracker™ green for 5 minutes at final
concentration of 5 μM, and the particles were quantified in Neubauer haemocytometer
using 40× objective and fluorescence microscope Olympus BX43 with camera Olympus
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DP21. Then, a total of 1,000,000 particles were plated in 30 μl of RPMI1 Seahorse-Agilent
pH 7.4 medium supplemented with glucose, sodium pyruvate, and L-glutamine, following
manufacturer’s instructions, in 96 well plate and centrifuged, as previously described for
live cells, and incubated for one hour in a CO2 free incubator. Then, 150 μl of the same
medium was add to each well. This protocol was repeated to determine OCR in live cells
and in live mitochondria.

Mitochondria Activity Assays
Enzymatic activity assays were conducted using the mitochondrial fraction
following the manufacturer’s instructions for the fumarase activity colorimetric assay kit
MAK206 (Sigma-Aldrich), aconitase activity assay kit MAK051 (Sigma-Aldrich), and
citrate synthase activity kit MAK193 (Sigma-Aldrich). The assays were carried out with
isolated mitochondrial protein using a mitochondrial isolation kit for cultured cells
(Thermofisher Scientific, Inc #89874, Pierce, Rockford, Waltham, MA), following the
manufacturer’s recommendations. Once the mitochondrial protein was obtained, it was
quantified using the BCA assay (standards prepared in Chaps buffer 2% in 1×TBS). All
protein concentrations were normalized to 1 μg/μl in assay buffer for each assay. A total
of 25-30 μg of mitochondrial protein was analyzed in each activity assay with replicates;
aconitase and citrate synthase activity was expressed in nmol/min/μL (milliunits/uLmU/uL) and fumarase nmol/min/mL (milliunits/mL- mU/mL).
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Oxidative stress and Reactive Oxygen Species detection
1. CellROX® Green Reagent and MitoTracker® Red FM
H441 lung epithelial cells were seeded on glass-bottom 35 mm dishes, silenced,
and exposed to normoxia and hyperoxia as previously described. H441 cells were stained
with CellROX® Green Reagent (Thermofisher Scientific, Inc # C10444, Pierce, Rockford,
Waltham, MA) to a final concentration of 5 μΜ in RPMI growth medium and incubated at
37°C. After 25 minutes of incubation, MitoTracker® Red (Thermofisher Scienific, Inc #
M22425, Pierce, Rockford, Waltham, MA) from 5μΜ stock concentration was added to
the cells to a final concentration of 25 nM. The resulting reaction mixture was incubated
for 5 more minutes for a total of 30 minutes of CellROX® incubation. The resulting
reaction mixture was incubated for 5 more minutes for a total of 30 minutes of CellROX®
incubation. The cells were then washed using DPBS and maintained in the growth
medium for imaging immediately on a Leica SP8 3X STED Laser Confocal Microscope
using 60× objective. The images were analyzed using the ImageJ-win64.Ink Fiji.app.

2. MitoSOX™ Red mitochondrial superoxide indicator
Lung epithelial cells H441 were plated on glass bottom 35 mm petri dishes. Once
the cells reached 60% confluency, they were treated with siRNA and incubated under
normoxic conditions for 48 hours as mentioned previously (for this assay the cells under
hyperoxia did not withstand the toxicity of staining), followed by incubation with
MitoSOX™ Red (Thermofisher Scientific, Inc # M36008, Pierce, Rockford, Waltham, MA)
to a final concentration of 5 μΜ in RPMI growth medium with incubation at 37°C. After 10
minutes of incubation with MitoSOX Red, MitoTracker® Green FM (Thermofisher
Scientific, Inc # M7514, Pierce, Rockford, Waltham, MA) from 5μΜ stock concentration
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was added to cells to a final concentration of 25 nM and incubated for 5 more minutes to
complete 15 minutes of MitoSOX™ incubation. Cells were washed with DPBS and kept
in growth medium to image immediately on a Leica SP8 3X STED Laser Confocal
Microscope using 60× objective. The images were analyzed utilizing the ImageJwin64.Ink Fiji.app.

Statistical Analysis
The data were expressed as mean ± SE. All the data were evaluated using IBM
SPSS Statistics (Version 26.0 Armonk, NY). Data were analyzed using ANOVA followed
by Tukey’s post-hoc test and multivariate analysis was conducted using two-way
MANOVA followed by Tukey’s post-hoc test for normally distributed data and p<0.05
considered statistically significant. Tables and graphics were constructed using Microsoft
Excel (2008). Adobe Photoshop 2020 was used for ensemble figures, keeping the original
images in adequate resolution.

Results
Hyperoxia induces a decrease in BMI1 levels in epithelial lung cells.
Small Airway Epithelial Cells (SAECs), H441 lung epithelial cells, and Human Lung
Microvascular Endothelial Cells (HMVEC-L) were exposed to normoxic (NO) and
hyperoxic (HO) conditions to determine BMI1 expression. Western blot analysis in whole
cell lysate indicates that the levels of BMI1 protein decreased significantly in epithelial
SAEC and H441 cells after 48 hours of HO (Figure 2.1 A & B). There were no significant
changes observed in endothelial cells (Figure 2.1 A) indicating that BMI1 expression is
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affected by high oxygen concentration in lung epithelial but not endothelial cells. The three
cell types were exposed to NO or HO at different time points (6h to 72h) to determine if
the expression of BMI1 is related to ALI. BMI1 protein expression increased in H441 cells
during the first 12h of hyperoxia exposure (Figure 2.1 B). This increase correlated with
apoptosis resistance, cell proliferation and growth, and inhibition of ROS accumulation as
a possible first response to the injury in these cells. No changes in BMI1 expression were
evident after 24h of HO versus NO exposure. The expression of BMI1 in SAECs is
relatively unchanged in the first 24h and decreases progressively during the oxygen
exposure period, up to 72h. Interestingly, BMI1 expression decreased significantly in
SAECs and H441 cells after 48h of hyperoxia, when oxidative stress, measured by an
increase in ROS production and autophagy, occurs (Figure 2.1 A & B) (156, 157).
A

B

Figure 2.1. BMI1 protein expression in three cell lines evaluated at different time points. Human Lung
Microvascular Endothelial Cells (HMVEC) in blue; Small Airway Epithelial Cells (SAEC) in red and H441
lung epithelial cells in green. A. BMI1 protein expression after different durations of exposure to hyperoxia
(western blot analysis). B. Densitometric analysis normalized to β-actin. N=6 (mean+/-SEM), one-way
ANOVA comparison of each time point to NO, * p-value ≤0.05, ** p-value ≤0.01
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Based on these findings, the authors question whether BMI1 is necessary for a
response to oxidative stress in HALI. Therefore, a pool of anti-BMI1 siRNAs was used,
and the best sequence was chosen to maximize the knockdown of BMI1 expression in
H441 cells.

BMI1 is necessary to respond to HALI in vitro:
1. Mitochondrial markers.
The expression of mitochondrial proteins (fusion, fission, etc.) was evaluated in
NO (Figure 2.2 A & C) and HO conditions (Figure 2.2 B & D) to evaluate the impact of
silencing BMI1 expression in mitochondria metabolism. The results show that the
expression of OPA1 (mitochondrial dynamin like GTPase) increases in BMI1 silenced
cells under both NO and HO conditions, with significant difference in expression under
NO (p = 0.040) (Table 2.1). Mitofusin 1 and 2 expression decreases after exposure to
HO, but their expression did not change significantly after BMI1 silencing. This indicates
that 42itofusin 1 and 2 expression is modified by the oxygen concentration but not by
BMI1 silencing (Figure 2.2 B). This study also demonstrates significant changes in DRP1
(dynamin like-1 protein) expression with hyperoxia. DRP1 is a fission protein that
facilitates mitophagy (158). The expression of DRP1 is influenced by the oxygen
concentration (NO versus HO) (Figure 2.2 A, B). An additive effect was observed between
BMI1 silencing and an increase in oxygen concentration, p = 0.016 for O2*siRNA (Figure
2.2 C & D, Table 2.1), evidenced by the decrease in the expression of DRP1 when BMI1
was silenced in H441 cells and exposed to HO. Aldehyde dehydrogenase 2 (ALDH2), a
mitochondrial protein involved in the oxidative metabolism of alcohol and a potential
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shield against oxidative stress (159), showed no significant changes following BMI1
silencing.
Table 2.1 Summary of P-values of two-way MANOVA for protein expression levels
Dependent variable

Independent
variable

OPA

MFN1

DRP1

ALDH2

pAKT

Pink1

Parkin

PTEN

DJ1

0.089

0.000

0.007

0.032

0.001

0.000

0.061

0.934

0.004

siRNA

0.040

0.977

0.015

0.835

0.006

0.146

0.028

0.001

0.119

O2* siRNA

0.147

0.932

0.016

0.315

0.008

0.050

0.016

0.884

0.001

O2 Concentration

2. Regulatory proteins of mitochondrial function.
Proteins involved in the PI3K/AKT pathway as well as mitochondrial regulator
proteins (widely studied in aging-associated diseases such as Parkinson’s disease and
Alzheimer’s disease) were evaluated after BMI1 silencing to further elucidate the
mechanism by which BMI1 acts in mitochondrial function. The expression of pAKT
(Ser473), Pink1, Parkin, and DJ1 was regulated for both oxygen concentration and
silencing of BMI1 (Table 2.1, Figure 2.3 A & B). The corresponding increase in pAKT and
Parkin levels was driven by BMI1 silencing while changes in the expression of Pink1 and
DJ1 were regulated by the oxygen concentration (Figure 2.3 A & B). PTEN, a tumor
suppressor that inhibits the PI3K/AKT survival pathway had a higher level of expression
when BMI1 was silenced, irrespective of hyperoxia exposure, evidencing the pivotal role
of BMI1 in cell survival and proliferation. (Figure 2.3 A & B, Table 2.1).
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A

B

C

D

Figure 2.2 Expression levels of mitochondrial proteins in Control and BMI1 silenced H441 Cells. A
Western blot for mitochondrial proteins in normoxic conditions and B hyperoxic conditions. C Densitometric
analysis of western blot normalized to β-actin in in normoxia. D Densitometric analysis of western blot
normalized to B-actin in hyperoxia. N=6, mean +/- SEM; ns=no significant, * p-value ≤0.05, ** p-value ≤0.01,
***p-value≤0.001.
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Table 2.2 Effect of Hyperoxia and BMI1 silencing in protein expression levels of mitochondrial
biomarkers and regulatory proteins of mitochondrial function

Treatment
Protein
Mitofusin 1
OPA1
DRP1
ALDH2
Pink1
Parkin
DJ1
PTEN
pAKT

BMI1 silencing

Hyperoxia

≈
↑↑
≈
≈
↑
↓
↑
↑
↓

↓
↓
↑
↓
↓↓
≈
↑
≈
↑↑

BMI1 silencing *
Hyperoxia

↓
↑
↑
↓
↓

↑↑
↑
↑
↑

These findings show that the silencing of BMI1 increases the expression of PTEN,
Pink1, and DJ1, under NO conditions, resulting in mitophagy. PTEN expression remained
elevated after HO in silenced cells. Parkin expression increased in silenced cells exposed
to hyperoxia in comparison with its expression under normoxia and vs non-silenced cells
in hyperoxia. Pink1 expression decreased in hyperoxia conditions vs normoxia for
silenced and non-silenced cells. pAKT expression increased under hyperoxia but this
increase was higher in non-silenced cells compared silenced (Figure 2.3 A, B). The
combination of these protein changes contributes to the inhibition of the PI3K-AKT
pathway and the activation of mitophagy. (Table 2.2). BMI1 expression regulates the
protein levels of Pink1-Parkin-DJ1 (proteins involved in mitochondrial quality control,
mitochondrial ubiquitination and mitophagy). The diminished levels of BMI1 in control
cells following HO, after silencing or both, induces mitochondrial dysfunction, loss of
mitochondrial membrane potential (ΔΨm), and an increase of oxidative stress that results
in mitophagy and ultimately cell death (Table 2.2, Figure 2.3).
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B

A

C

D

Figure 2.3. Expression levels of regulatory proteins of mitochondrial function in Control and BMI1
silenced H441 Cells. Western blot for protein expression in A. normoxic and B. hyperoxic conditions
Densitometric analysis of western blot normalized to β-actin in C. normoxia and D. hyperoxia n=6, mean
+/- SEM; ns=no significant * p-value ≤0.05, ** p-value ≤0.01.
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BMI1 silencing changes the levels of gene transcripts in a different manner
relative to the levels of protein expression.
Gene transcripts were analyzed through quantitative RT-PCR, using TaqMan RTqPCR probes and β-actin as the internal calibrator to better understand if the impact of
BMI1 silencing on protein expression was regulated at the transcriptomic level. Data,
analyzed by two-way MANOVA (Table 2.3), show that oxygen concentration significantly
decreased (p < 0.05) the expression levels of gene transcripts encoding proteins involved
in mitophagy (Pink1, Parkin, and DJ1) and cell survival (PTEN, BCL2, and NRF2).
Moreover, a combination of high O2 concentration and BMI1 silencing diminish the
transcript levels of TIMM23, Parkin, DJ1, and BCL2. However, simple comparison
analysis (Figure 2.4, Table 2.4) shows that silencing of BMI1, in combination with
hyperoxia, induces a significant decrease in transcripts of TIMM23, genes encoding for
mitochondrial fusion proteins (MFN1 and OPA1), for proteins involved in mitophagy
(Pink1, Parkin), in cell survival (PTEN), anti-apoptosis (BCL2), and oxidation (NRF2), as
well as increases the transcript levels of NLRP3 gene encoding the NLRP3
inflammasome protein. Nevertheless, the transcript levels did not correspond with their
protein expression levels, indicating that posttranscriptional modifications and other
pathway signals are implicated in the regulation of protein synthesis.

BMI1 silencing interferes with mitochondrial respiration.
An oxygen consumption rate (OCR) analysis was performed on H441 cells and
their live mitochondria to determine if BMI1 silencing affects mitochondrial function. In
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both cases, the consumption of oxygen was significantly higher in non-silenced cells
under
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Figure 2.4. q-RT-PCR, relative fold change of transcripts compared with β-Actin.
A Transcripts of mitophagy genes. B Transcripts of genes involved with ALI. C Transcripts of
mitochondria biomarkers. N=3 (mean+/-SEM), simple comparisons between oxygen concentration
(normoxia and hyperoxia) and siRNA (control siRNA and BMI1 siRNA), ns=not significant, * p-value
≤0.05, ** p-value ≤0.01, ***p-value ≤0.001

normoxic conditions than in BMI1 silenced cells exposed to hyperoxia (Figure 2.5 A & B
***p < 0.001). The basal respiration level was around 20.0 pmol/min for non-silenced cells
in NO but was almost undetectable in cells exposed to HO, BMI1 silencing or both (Figure
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2.5 A & C). The energy map indicates that these cells had an energetic phenotype (Figure
2.5 A), producing approximately 17 pmol/min of ATP as their main energy source (Figure
2.5 E). Silenced H441cells in NO utilized glycolysis as an energy source while the cells
exposed to HO turned to the quiescent phenotype (Figure 2.5 A- energy map).
Live mitochondria derived from the non-silenced cells in NO had a significantly
higher consumption of oxygen (110 pmol/min) than mitochondria derived from silenced
cells, or cells exposed to hyperoxia (Figure 2.5 B & D). Mitochondria from non-silenced
cells in NO showed an energetic phenotype with higher ATP production (60 pmol/min)
(Figure 2.5 F). An OCR vs time curve for the live mitochondria showed a similar trend to
that observed in the live cells. The absolute values of basal respiration, spare respiratory
capacity, ATP production, and proton leak were three-fold higher for live mitochondria
isolated from non-silenced cells in NO and HO than for live H441 cells under the same
oxygen conditions (Figure 2.5 A, B, C & F). However, the consumption of O2 by cells and
live mitochondria obtained from silenced cells in hyperoxia did not show differences in
magnitude. The energy map for mitochondria-derived H441 cells silenced for BMI1 and
exposed to hyperoxia demonstrated a quiescent phenotype in terms of oxygen
consumption (same that was shown for H441 cells) (Figure 2.5).
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Table 2.3. Summary of P-values of two-way MANOVA for transcript levels
Independent

Dependent variable

variable

BMI1

TIMM23

MFN1

MFN2

OPA1

DRP1

FIS1

Pink1

Parkin

DJ1

PTEN

AKT

NLRP3

BCL2

NRF2

O2 Concentration

0.071

0.003

0.000

0.374

0.002

0.319

0.058

0.000

0.000

0.046

0.000

0.122

0.987

0.000

0.001

siRNA

0.000

0.850

0.011

0.464

0.082

0.660

0.669

0.477

0.007

0.275

0.080

0.806

0.001

0.000

0.115

O2* siRNA

0.813

0.036

0.893

0.962

0.759

0.920

0.754

0.895

0.016

0.034

0.249

0.464

0.255

0.000

0.263

Table 2.4. Effect of Hyperoxia and BMI1 silencing in gene transcripts levels based on simple comparisons analysis
Transcript
BMI1
TIMM23
Mitofusin 1
Mitofusin 2
OPA1
DRP1
FIS1
Pink1
Parkin
DJ1
PTEN
AKT
NLRP3
BCL2
NRF2

Treatment
Hyperoxia

BMI1 silencing

↓
↑
≈
≈
≈
≈
≈
≈
↑
≈
≈
≈
↑
↓↓
↓

≈
≈
↓
≈
↓
≈
≈
↓
↓↓↓
≈
↓
≈
≈
↓↓
↓
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BMI1 silencing * Hyperoxia

↓↓
↓↓
↓↓↓
≈
↓↓
≈
≈
↓
↓↓↓
≈
↓
≈
↑
↓↓↓
↓

B

A
Oligomycin

Control siRNA NO
siRNA HO

OCR (pmol/min)

C

FCCP

*** *** ***

Oligomycin

Rotenone/

BMI1 siRNA NO

FCCP
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Rotenone/

BMI1

D
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*** *** ***
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Figure 2.5 Oxygen Consumption Rate. (A, C, E), Oxygen consumption rate in H441 complete cells.
Basal respiration, maximal respiration, proton leak, and ATP production are higher in cells with normal BMI1
expression in normoxic conditions showing energetic production of energy. (B, D, F), Oxygen consumption
rate in live mitochondria isolated from H441 cells. Basal respiration, maximal respiration, proton leak, and
ATP production are higher in live mitochondria with normal BMI1 expression in normoxic conditions showing
energetic production of energy. Cells and mitochondria obtain the energy via glycolysis after BMI1 silencing
and exposure to hyperoxia. Respiration parameters showed higher values in live mitochondria than in
complete cells but maintain the same trend for each treatment confirming the effect of BMI1 silencing and
hyperoxia.
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BMI1 silencing and hyperoxia promote mitochondrial dysfunction in the
enzymes from the tricarboxylic acid cycle (TCA).
Mitochondria from H441 cells were isolated after treatment with control or BMI1
siRNAs, followed by NO or HO treatment to investigate mitochondrial functionality. Three
different activity assays were performed: 1. Fumarase activity in mitochondria decreased
significantly, both after BMI1 silencing (p = 0.0014) and under HO conditions (p = 0.024)
(Figure 2.6 A); 2. Aconitase activity decreased significantly in mitochondria, providing
evidence for additive deleterious effects when BMI1-silenced cells are exposed to
hyperoxia (Figure 2.6 B). The decrease in aconitase activity, in both NO and HO, was
significantly greater after BMI1 silencing versus non-silencing; and 3. There were no
significant differences in citrate synthase activity in mitochondria isolated from H441 cells
exposed to normoxic conditions (silenced for BMI1 or non-silenced). However, citrate
synthase activity decreased substantially in hyperoxia-exposed mitochondria derived
from H441 cells compared to normoxia; this reduction was worse in mitochondria from
cells subjected to both hyperoxia and BMI1 silencing (Figure 2.6 C). The results of these
enzymatic activity assays demonstrate that BMI1 is necessary for mitochondria to
respond to the damage caused by hyperoxia and to properly carry out the TCA cycle
(tricarboxylic acid cycle/Krebs cycle).
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Figure 2.6. Mitochondria Activity Assays. A Fumarase (nmol/min/uL) showed a significant decrease in
activity after BMI1 silencing in NO and HO. B Aconitase (nmol/min/mL) showed a significant decrease in
activity after hyperoxia and a greater decrease after BMI1 silencing evidencing the additive deleterious
effect of HO and BMI1 silencing. C Citrate synthase (nmol/min/uL) did not show a significant difference
between non-silenced and silenced H441 cells for BMI1 expression under normoxic conditions, the activity
was significantly different in hyperoxic conditions where the silencing of BMI1 has an additive deleterious
effect. N=3, mean +/- SEM; two-way MANOVA ns=non-significant * p-value ≤0.05, ** p-value ≤0.01, ***pvalue≤0.001.
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Oxidative stress and ROS production increases after BMI1 silencing,
leading to mitochondrial dysfunction.
Contrast confocal microscopy image analysis was used to determine the
mitochondrial phenotype and function to characterize H441 cell mitochondria after BMI1
silencing. MitoTracker™ Red and Cell-Rox™ Green dyes were used to detect
mitochondria and oxidative stress, respectively, thus allowing for co-localization. H441
cells were more readily detached after BMI1 silencing and hyperoxia, and oxidative stress
was significantly higher after exposure to hyperoxia versus normoxia (as evidenced by
the increase in green fluorescence) (Figure 2.7 A & B). Superoxide ion production was
assessed using MitoSox™ Red dye to visualize detectable changes in mitochondrial
function. This analysis reveals that BMI1-silenced cells produce significantly more ROS,
as evidenced by an increase in red fluorescence (Figure 2.7 C and D).

Discussion
Hyperoxia induces mitochondrial damage, cell death, and DNA fragmentation (68,
70, 71, 73), all characteristic signs of ALI. Based on this description, HALI represents a
useful approach for studying ALI/ARDS in vivo and in vitro. Diminished expression of
BMI1 is associated with increased mitochondrial ROS production, ETC alterations, and
activation of the DDR pathway (133, 134, 160). This study provides new insight into
mitochondrial dysfunction in ALI.
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Figure 2.7 Mitochondria staining. A Hyperoxia increases the oxidative stress in mitochondria, evidenced
by augmented fluorescence with CellROX Green staining that is colocalized with MitoTracker Red.
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BMI1 siRNA

Control
siRNA
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B

D

Figure 2.7 Mitochondria staining. Continued. B mean signal intensity determined for CellROX staining.
C-D BMI1 silencing induces ROS production raising superoxide ion (O2−), MitoSOX Red staining
determined this increase by the intensity of red fluorescence; n>10, mean +/- SEM; two-way MANOVA
ns=no significant * p-value ≤0.05, ** p-value ≤0.01, ***p-value≤0.001.

This research shows that markers of mitochondrial dynamics can be regulated by
BMI1, and that changes in the levels of proteins involved in this dynamic process are
possibly due to a compensatory mechanism to evade mitophagy and cell death (Table
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2.2, Figure 2.2). The expression of DRP1 increases under hyperoxia conditions. DRP1 is
crucial to mitochondrial fission and its levels increase to remove damaged mitochondria
through mitophagy. Consequently, its degree of expression is a normal aspect of cell
metabolism and mitochondrial dynamics, but also a notable compensatory response for
disease and cell death (106, 161-163). It is necessary to maintain a balance between the
mitochondrial fusion and fission proteins for mitochondrial health and biogenesis.
Impairment of mitochondrial fusion and fission effectively increase mitophagy in AECII,
as has been observed in lung emphysema and chronic obstructive pulmonary disease
(COPD) (161). These findings show an imbalance between the fusion proteins, OPA1,
MFN1, and MFN2, and fission protein, DRP1 (Table 2.1 and Figure 2.2). It illustrates a
net shift in the mitochondrial activity network to favor mitophagy. Furthermore, there are
significant differences in mRNA expression of MFN1 and OPA1 measured by qRT-PCR
analysis of transcript levels (Figure 2.4 C, Table 2.3).
Previous studies have evaluated the involvement of the PI3K-AKT pathway in ALI,
either as controlling damage and activating survival or inducing apoptosis and cell death.
Kolliputi et al. (2009) demonstrated that IL-6 overexpression protects against HALI via the
PI3K-AKT pathway (71). In addition, Shi et al. (2019) found that the PI3K-AKT pathway
regulates mitochondria and attenuates endotoxin-induced ALI by heme oxygenase-1
(HO-1) induction, which protects the cell from the damage caused by sepsis (103). In the
current study, no changes in AKT transcript levels were observed in response to oxygen
concentration or BMI1 silencing (Figure 2.4 A). However, there were changes in the
expression of pAKT (Ser473) mediated by hyperoxia and BMI1 silencing (Table 2.1,
Figure 2.3). The increase in the levels of AKT phosphorylated at Ser473 is linked to cell
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protection (164, 165). It could be a cellular response to injury caused by hyperoxia, but
this response is insufficient when BMI1 silencing is also added (Figure 2.3 D).
Western blot data show that PTEN levels increased in a BMI1-silencing dependent
manner (Figure 2.3, Table 2.1). BMI1 and PTEN have two known methods of regulation,
wherein BMI1 overexpression inhibits PTEN expression (at least in nasopharyngeal
epithelial cells) (166), and, in turn, PTEN may abrogate BMI1 function and expression in
cancers, such as prostate cancer or cardiac fibroblasts (139, 165, 167, 168). PTEN
catalyzes the dephosphorylation of PIP3 (phosphatidylinositol 3,4,5-trisphosphate) to
produce PIP2 (phosphatidylinositol 4,5-bisphosphate), thereby suppressing the Akt/PKB
signaling pathway. This regulates cell growth and survival and is linked to mitochondrial
function and metabolism (167, 169). These results corroborate the pivotal role that BMI1
plays in cell survival and renewal and highlight the importance of BMI1 normal expression
in lung epithelia in response to the injury caused by hyperoxia.
The effect of BMI1 on the expression of Pink1, Parkin, and DJ1 is of special interest
as well. In fact, these proteins are involved in ubiquitination and mitophagy and are
associated with the pathogenesis of Parkinson’s disease (169-172). The impact of
alteration in the expression levels of Pink1/Parkin has been studied in LALI and
demonstrate that these proteins, due to their role as homeostatic regulators of mitophagy,
are necessary for a response in sepsis (119). This study helps establish the significant
impact of both BMI1 silencing and hyperoxia on the increase in the expression of Pink1
and Parkin, which, in turn, induces more mitochondrial dysfunction and mitophagy (Figure
2.3, Tables 2.1 and 2.2). Dye et al. (2015) demonstrated that BMI1 depletion induced
mitophagy and cell death via necroptosis in an ovarian cancer cell line (140). The qRT-
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PCR results (Tables 2.3 and 2.4 and Figure 2.4) suggest that enhanced changes in the
transcript levels may be mediated by oxygen concentration rather than BMI1 silencing,
and the impact of the latter is more evident at the protein level. The transcript levels for
the NLRP3 inflammasome, BCL2, and NRF2 agree with the results of previous studies
reported in HALI by our group (68, 73, 173).
Previously, Sanchez and colleagues (2020) found that T80, HeLa, 293T and U2OS
cells silenced for BMI1 had retardation in the cell cycle and caused replication stress by
increasing instability at common fragile sites (sites of DNA instability). In mouse
embryonic fibroblast (MEF) cells, BMI1 silencing produced chromosome breakages after
injury with stressors such as HU (hydroxyurea) or APH (Aphidicolin). These authors
hypothesized that BMI1 has control over RNA polymerase II, arresting transcription
regions. This finding in our study could indicate that the impact of BMI1 silencing in
mitochondria dynamic proteins and mitochondrial metabolism could be indirect, acting at
the nuclear level with hyperoxia acting as a stressor, exacerbating the metabolic changes
induced by BMI1 silencing.
The same group found an increase in γH2AX, a phosphorylated histone variant,
after BMI1 silencing in their cancer cell lines; we observed that increase in non-silenced
cells exposed to hyperoxic conditions (Appendix 3). This finding could indicate that our
cultured lung epithelial cells may have alterations in other proteins of the DDR pathway
such as CBX4 previously related with the SUMOylation of BMI1 in DNA damage sites
(174). Liu and collaborators (2009) found that BMI1 deletion caused engagement of the
DDR pathway and DNA damage that possibly could involve not only nuclear DNA but
mitochondrial DNA (134).
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In supplementary data of this study, we showed increased protein levels of IFI16
(inflammasome marker) after BMI1 silencing. This may indicate the impact of BMI1
silencing in triggering the inflammasome pathway, as was shown in a recent work where
the quercetin increases BMI1 expression in a model of cardiopulmonary resuscitation of
rats, with a subsequent decrease in both ROS production and inflammation (175)
(Appendix 3). Another finding was the increase of E-cadherin (cell adhesion molecule)
after BMI1 silencing that could be related to the cellular response to the damage caused
by BMI1 silencing. However, we observed that H441 BMI1-silenced cells were more
prone to detach than non-silenced cells.
Measurement of oxygen consumption is a method used to assess mitochondrial
functionality and respiration in cells or isolated viable mitochondria (176). In this study, a
new approach to obtain live mitochondria from H441 lung epithelial cells was
standardized; OCR was determined in intact H441 cells and in live mitochondria isolated
from H441 cells after silencing and hyperoxia exposure. Analysis of OCR in both cells
and isolated mitochondria revealed the same respiratory profile (Figure 2.5). Nonsilenced H441 cells and mitochondria in normoxia conditions had high basal respiration,
ATP production, and energetic phenotype (Figure 2.5 C-F). Previously, it was reported
that hyperoxia reduces mitochondrial respiration rate in MLE-12 (mouse lung epithelial
cells) (177). However, in the current study, BMI1 silencing and hyperoxia were a lethal
combination for mitochondrial health, leading cells to seek alternative energy resources
through the glycolytic pathway or inducing senescence in cells and isolated mitochondria
(Figure 2.5 A and B).
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The tricarboxylic acid cycle (Krebs cycle) is the primary source of aerobic energy
and cellular metabolism (178). Therefore, evaluation of the enzymatic activity of several
enzymes involved in the TCA cycle, such as fumarase, aconitase, and citrate synthase,
was evaluated as a marker for oxidative stress (179, 180). A significant decrease in
enzymatic activity after the silencing of BMI1 was further worsened following the damage
caused by hyperoxia (Figure 2.6). A decrease in aconitase activity with constant fumarase
activity suggests oxidative stress (179). Mitochondria from silenced cells had lower
aconitase activity (0.82 nmol/min/mL) after hyperoxia compared with mitochondria from
normoxia and non-silenced cells (1.33 nmol/min/mL). Fumarase activity values were 0.68
nmol/min/mL and 0.72 nmol/min/mL, respectively, even though the changes in fumarase
were significantly different between control siRNA NO versus BMI1 siRNA HO groups,
indicating an increment in oxidative stress.
Double fluorescence staining was performed to co-localize ROS production and
mitochondrial oxidative stress. BMI1-silenced H441 cells produced more ROS and had
more oxidative stress than non-silenced cells (Figure 2.7 A and B). CellROX® Green is a
fluorogenic reagent designed to measure ROS in live cells. In the reduced state, the
green fluorescence is weak, and after oxidation by ROS and subsequent binding to
DNA, the fluorescence becomes brighter. The images indicate higher ROS levels after
hyperoxia and BMI1 silencing. Mitosox® Red was used to measure ROS production in
the form of superoxide ion, which results from the ETC. The latter increases peroxide
H2O2 production (superoxide also inactivates aconitase through oxidation of its ironsulfur core) (181). This agrees with the findings of this study (Figure 2.7 C and D),
where the silencing of BMI1 induced more ROS production than in the non-silenced
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cells, as evidenced by the red fluorescence p=0.0080. Furthermore, the inactivation of
aconitase shows oxidative stress and mitochondrial dysfunction. The fundings of this
chapter has been accepted for publication in the Journal: Frontiers in Physiology,
section Redox Physiology (Appendix 1).

Limitations of the in vitro model and Future Directions
Our in vitro model used H441 lung epithelial cells; these cells express mRNA and
major surfactant protein as AECII and they have lamellar bodies like Clara cells. This cell
line has been used by our laboratory and described in our publications because of the
features of epithelial lung cells; it is easy to maintain under in vitro conditions; the cells
can be used until passage 25 without phenotypic changes in growth, speed of expansion,
survival. However, will be interesting to confirm our results using an epithelial type II cell
line.
Hyperoxia induces vascular damage mediated by inflammation, apoptosis and
necrosis in human neonatal veins (182); in animal models it induces alterations in
angiogenesis and vasculogenesis by reducing G1 phase length and increasing S phase
in cell cycle (183). We previously found an increase in cytochrome C, BAX and ALDH2 in
HMVEC-L cells after 48h of hyperoxia (184), but we did not changes in BMI1 expression
levels under the same conditions. We suggest evaluating BMI1 expression after
hyperoxia exposure in another endothelial cell line to test the effect of hyperoxia in BMI1
expression in endothelial cells.
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Due to the limited time of knockdown expression using siRNA, we recommend
using CRISPR to induce stable silencing of BMI1 in epithelial cells, followed by hyperoxia
exposure and evaluation of mitochondrial markers at different time points.
We were unable to complete immunoprecipitation experiments due to the high cost
and small number of BMI1 antibodies commercially available. These experiments would
allow us to determine BMI1 interacting/binding partners.
We suggest evaluating future markers of mitochondrial biogenesis such as PARIS,
PGC-1α, ERR, RxR, PPARγ, COX1, CYTB, NRF1 to determine if mitochondrial impaired
function after BMI1 silencing is determined in the biogenesis process (185).
We recommend evaluating mitochondria heteroplasmy to determine if it occurs
after hyperoxia, after BMI1 silencing or both (186, 187).
It will be interesting to determine if the effect of BMI1 in mitochondrial function is
direct or indirect; for that purpose, it would be necessary to evaluate the possibility of
inhibiting or suppressing the NLS (nuclear localization signal) motifs of BMI1 protein and
verify the effects in downstream mitochondrial function. Similarly, the DNA binding
domain (RING) or the Polycomb binding domain (HTH) could be suppressed separately
to determine the implications of this specific loss of function in Bmi1 protein and the
effect(s) on mitochondrial physiology.
PRC1 containing has the function of monoubiquitinating histone H2A at Lys-119,
repressing transcription of CpG island containing promoters in mammalian cells (133,
188-190); in this project we did not evaluate other proteins of PRC1 or any of the known
repressed genes downstream of BMI1 such as Ink4a/Arf locus (p16Ink4a and p19Arf) (191).
However, to determine if the impact of BMI1 silencing or deletion in mitochondrial
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dysfunction is direct or indirect (via gene repression), it would be necessary to evaluate
mitochondrial function after chromatin repression in a BMI1-dependent or BMI1independent manner (192).
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Chapter 3: Critical Role of BMI1 in ALI/ARDS in vivo model. Bmi1
knockout mice

Background
Nathalie van der Lugt and colleagues (1994) generated BMI1 null mutant mice.
They used homologous recombination in embryonic stem cells to induce inactivation of
the bmi-1 gene in germline. Researchers eliminated the start codon, the zinc finger motif,
and part of the HTH motif to produce the knockout Bmi1 mice (Bmi1־/‐). These mice were
obtained by breeding heterozygous progenitors due to the infertility of the null
homozygous genotype. Using this breeding strategy, 25% of the offspring are Bmi1־/‐; only
50% survive after the first three days of birth and the remaining 50% die before 20 weeks
of age. The phenotype of Bmi1-deficient mice is characterized by small size and low
weight; these mice have neurologic alterations such as ataxia, tremors, and seizures;
hematopoietic abnormalities (small development of thymus, spleen, liver, and failure in
bone marrow cells production). Bmi1 genetic depleted mice have a reduced cellular and
humoral immune response (decreased lymphopoiesis and myelopoiesis) with high
susceptibility to opportunistic infections, and changes in bone morphology (137) (Figure
3.1).

BMI1 protein levels are elevated in several human cancers such as prostate,

myeloid leukemia, gastrointestinal cancer, bladder, breast, etc.; however, maintaining
BMI1 protein is necessary for cell growth, renewal, and survival. Human lung epithelial
cells studied in the previous chapter showed an additive deleterious effect between the
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decrease of BMI1 protein levels and hyperoxia injury; in this chapter we evaluate the
susceptibility of Bmi1 knockout mice to develop mitochondrial dysfunction in HALI.

A

B

P

WT
WT
KO

KO
Figure 3.1 Experimental animals. A. Comparison of sizes P (progenitor) 20 weeks old and WT (wild-type)
and KO (Bmi1־/‐) 9 weeks old. B. Detail of WT and KO mice.

Materials and Methods
Experimental Animals
Heterozygous Bmi1(⁺/‐) mice were obtained from The Jackson Laboratory (stock
No: 024584, Allele Symbol: Bmi1tm1Brn) and backcrossed with FVB wild-type (WT) mice
for 4 generations to establish the colony. Heterozygous mice were bred to obtain all the
genotypes for future experiments and colony maintenance. The University of South
Florida Institutional Animal Care and Use Committee (IACUC) approved all animal
experiments (Appendix 5). The mice remained housed in the USF Comparative Medicine
facility in isolated cages, with 12 hours of the light-dark cycle at room temperature (22 ±
1°C); all mice were fed ad libitum with regular diet while knockout (KO) mice also received
hydrogel, and fat and protein-rich food ad libitum.
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In vivo Hyperoxia Model
Bmi1 knockout mice and their WT littermates were used for experimentation at
nine weeks old. Mice were exposed to normoxic (21% O2) or hyperoxic (O2 >95%)
conditions for 48 hours to induce HALI, in an airtight chamber (70x50x50cm) as
previously described (70, 73, 193). Oxygen was monitored using ProOx 110 controller
(BioSpherix, NY). After treatment, mice were anesthetized with ketamine/xylazine and
then euthanized. Lungs were perfused with sterile phosphate buffered saline (PBS) and
collected (frozen in liquid nitrogen for protein and RNA isolation or activity assays; fixed
in paraformaldehyde for histology, or immediately processed for live mitochondria
isolation).

Protein isolation and western blot
After lung collection, tissue was stored in liquid nitrogen until use. Lung protein
was obtained by tissue pulverization using a liquid nitrogen-cooled steel pulverizer and
resuspending in protein isolation buffer as mentioned in the Chapter 2 methods section.

Western blot analysis
Protein expression was analyzed by loading 10 μg of lung lysate from WT and
Bmi1־/‐ mice exposed to NO or HO conditions on 10% or gradient SDS-PAGE (4-20%).
The proteins were transferred to PVDF membrane, blocked in 5% BSA in TBST for 1 hour
at room temperature and then incubated with primary antibody overnight at 4°C. After
washes, secondary antibody was added and incubated 1 hour at room temperature,
followed by washing and ECL development as described in Chapter 2 methods. Proteins
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were quantified using ImageJ (NIH, Bethesda, MD) and normalized to β-actin (antibodies
and conditions are listed in Appendix 2).

Live mitochondrial isolation and mitochondrial proteins
Live mitochondria were isolated from mouse lungs with some modification of the
protocol published by Hartwig et al., 2015 (155). Mice were euthanized, and whole-body
perfusion was completed with 5ml of sterile PBS; lungs kept on ice in cold homogenization
buffer (HB) containing sucrose, EGTA, mannitol, DTT, NaCl, and KCl. Then, lung tissue
was cut with a blade into small pieces and ground 10 times in a plastic disposable
homogenizer with two volumes of cold homogenization buffer (68itofus. 500ul). The
homogenate, kept cold on ice, was passed through a syringe with a 27-gauge needle 10
times and centrifuged 666×g at 4°C for 15 minutes. The supernatant was transferred to a
new 2ml tube and the volume was brought up to 1.8ml with homogenization buffer and
centrifuged at 11000×g 4°C for 15 minutes. The decanted supernatant contained cytosolic
proteins was stored at -80°C; the pellet was washed with HB by pipetting carefully without
disturbing, then was resuspended in 1ml of HB and centrifuged again at 11000×g 4°C for
15 minutes.
The supernatant wash was discarded, and the pellet was resuspended in 1 ml of
HB. The resuspended pellet was overlaid with a 2, 1.5, and 1 M sucrose gradient prepared
in HB (in 13.2ml open-top thin-wall ultra-clear tubes) and centrifuged at 85000 ×g 4°C for
1 hour without brake (Optima XPN-90 Ultracentrifuge with SW-41 Ti Swinging-Bucket
Rotor, Beckman Coulter, Indianapolis, IN).
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The mitochondrial fraction was obtained from the middle layer. Mitochondria were
resuspended in the cell growth medium for the OCR experiment. Mitochondrial proteins
were quantified with Pierce™ Detergent Compatible Bradford Assay Reagent and then
stored frozen at -80°C.

Reverse transcription quantitative polymerase chain reaction (RT-qPCR)
Total RNA was isolated from lung tissue using Rneasy Mini Kit® from Qiagen
(Germantown, MD), purified with Rnase-free Dnase set (Qiagen), dissolved in Rnasefree water and stored at -80°C. For reverse transcription PCR (RT-PCR), iScript cDNA
synthesis Kit (BioRad, Hercules, CA) was used following the manufacturer’s instructions
and 1 μg of total RNA was reverse transcribed. To verify that knockout mice did not
have the transcript for Bmi1, quantitative RT-PCR was performed using cDNAs and
TaqMan qRT-PCR probes: Bmi1(Mm00776122_gH), β-Actin (Mm02619580_g1). The
qRT-PCR experiments were analyzed in a QuantStudio 3 PCR System (Life
Technologies) according to the manufacturer’s instructions for TaqMan probes and
TaqMan Fast Advanced Master Mix. Data was analyzed by ΔΔCt method using β-actin
(internal calibrator).

Measurement of oxygen consumption rate (OCR)
Oxygen consumption rates were determined using a Seahorse Xfe96 Analyzer
(Seahorse Biosciences, North Billerica, MA). Live mitochondria derived from lung tissue
were isolated from WT and KO mice exposed to normoxic and hyperoxic conditions. The
OCR experiment was completed as described for live mitochondria in the in vitro model.
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Briefly, live mitochondria were isolated from lungs modifying the protocol described in
Hartwig 2015 for lung cells (155). Lungs were weighted and homogenized with buffer
containing sucrose, EGTA, mannitol, DTT, NaCl, and KCl, a total of twice the weight in
microliters was used to cut the tissue and grind with biomasher. After tissue grinded the
solution was pass through 1ml syringe with 30G needle and then the homogenized
solution was ultra-centrifugated in a sucrose gradient prepared in the homogenization
buffer at concentrations of 2, 1.5, and 1 M. Mitochondria were collected from the middle
layer and stained with MitoTracker™ Green for 5 minutes at a final concentration of 5 μM.
The number of particles was quantified in a hemocytometer using a 40× objective and
Olympus BX43 fluorescence microscope with Olympus DP21 camera. A total of
1,000,000 particles were plated in 30 μl of RPMI1 Seahorse-Agilent pH 7.4 medium
supplemented with glucose, sodium pyruvate, and L-glutamine, following the
manufacturer’s instructions, in 96 well plates and centrifuged followed by incubation for 1
hour in a CO2 free incubator. Then, 150 μl of Seahorse pH 7.4 RPMI medium was added
to each well and OCR was measured.

Mitochondria Activity Assays
Fumarase, aconitase and citrate synthase activity assays were conducted using
the mitochondrial fraction following the manufacturer’s instructions (MAK206, MAK051
and MAK193 kits from Sigma-Aldrich). The assays were performed with mitochondrial
protein isolated with a mitochondrial isolation kit for tissue (Thermofisher Scientific, Inc,
catalog 89801, Pierce, Rockford, Waltham, MA) following the manufacturer’s
recommendations. Mitochondrial protein was quantified using BCA assay (standards
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prepared in Chaps buffer 2% in 1×TBS). Protein concentration was equalized to 1 μg/μl
in assay buffer for each enzymatic activity. A total of 25 μg of mitochondrial protein was
analyzed in each activity assay in duplicate. Citrate synthase and aconitase activities
were expressed in nmol/min/μL (milliunits/uL-mU/uL) and fumarase activity was reported
in nmol/min/mL (milliunits/mL- mU/mL).

Lung Histology
Left lungs were fixed in 4% paraformaldehyde (PFA), processed and sectioned by
the Moffitt Cancer Center Tissue Core. Tissue sections stained with hematoxylin and
eosin (H&E) were analyzed using 20× and 40× objectives on a Keyence BZ-X710
microscope to obtain acute lung injury score (ALIS). The parameters for ALIS were the
presence of peribronchiolar infiltrates, hemorrhage, cellular infiltration into alveoli
(leucocyte or aggregation of neutrophils), increase of interstitial thickening, and alveolar
edema. Scores from zero to four were assigned as follows: 0 for normal lung without
damage, 1 for mild damage <25% lung involvement; 2 for moderate damage, 25–50%
lung involvement); 3 for severe damage, 50-75% lung involvement; and 4 for severe
damage, >75% of the lung (194-198).

Bronchoalveolar lavage fluid (BALF) analysis and cell counting.
BALF was collected by instillation of 3 ml of DPBS (1ml three times) into the lung
via tracheal intubation using a 20G or 22G peripheral IV catheter for WT or Bmi1-/- mice,
respectively. BALF was centrifuged at 400×g in 4°C for 10 min. The supernatant was
transferred to a clean tube and stored at -80°C until further use. Pellets contained the
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cells were resuspended in 1 ml DPBS. Total protein concentration in BALF was
completed

using

the

BCA

protein

assay

following

the

manufacturer’s

recommendations (ThermoFisher Scientific, Inc, catalog 23225, Pierce, Rockford,
Waltham, MA).
Total cell number was estimated by counting in a hemocytometer using a 40×
objective on an Olympus BX43 microscope with Olympus DP21 camera. For differential
cell counting, 200 µl of cellular suspension was layered onto glass slides using a cytospin
cytocentrifuge at 800rpm for 5 minutes. Slides were stained with Diff-Quik (Fisher
Scientific) with total immersion for 10 sec in fixative solution, 10 sec in solution I, and 7
sec in solution II, followed by air-drying at RT and counting using an Olympus BX43
microscope (199, 200).

Lung capillary leak assessment.
Wild-type and knockout Bmi1 mice exposed to 48 hours of normoxia or hyperoxia
were weighed and Evans blue dye (EBD; Sigma-Aldrich) stock solution prepared at
0.5% (0.005mg/μl) in PBS was injected into the tail vein at a dose of 50 mg/kg (10ul of
EBD 0.5% per gram of weight). After 30 min, the animals were euthanized and the lungs
were perfused with 3 ml of DPBS via the right ventricle, followed by BALF collection as
previously described (194, 201-203). The lungs were excised, photographed, and frozen
in liquid nitrogen until further use. Lung capillary permeability was measured in the BALF
stained with EBD, reading the absorbance at 630 nm in a spectrophotometer.
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Dynamic lung function measurements
Division of Comparative Medicine technical personnel anesthetized and
intubated the mice and completed lung function measurements. WT and KO mice at 9
weeks of age were exposed to normoxic or hyperoxic conditions (6 per group). The
animals received an intraperitoneal injection of dexmedetomidine (0.5 mg/kg) to induce
sedation and reduce anxiety prior to intubation followed by administration of the
anesthetic, 100 mg/kg ketamine+10 mg/kg xylazine. Each catheter was calibrated prior
to use; 20 and 22G catheters were used for WT and KO mice respectively. The mice
were intubated after catheter calibration and they were maintained under anesthesia
using isoflurane (3-4% induction, 1-2% maintenance/inhalation) delivered with oxygen
using a calibrated vaporizer.
Each lung function experiment began with a “Deep Inflation” to standardize lung
volume and verify the catheter’s proper insertion. Baseline airway compliance and
resistance were measured in triplicate (SnapShot-150, Quick Prime-3, and pressuredriven perturbation); the protocol was repeated twice (204, 205). All the parameters,
respiratory system elastance (Ers), tissue elastance (H), static compliance (Cst), tissue
damping (G), Newtonian resistance (Rn), and respiratory system resistance (Rrs),
inspiratory capacity (IC), were measured using a piston ventilator (FlexiVent, SCIREQ
Inc., Montreal, Canada). To maintain body temperature, the mice were placed on a
circulating warm water pad and this was a non-survival procedure.
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Statistical Analysis
The normoxia/hyperoxia experiments were performed at least twice; the data were
expressed as mean ± SE and evaluated using IBM SPSS Statistics (Version 26.0 Armonk,
NY). Data were analyzed using ANOVA or two-way MANOVA followed by Tukey’s posthoc test for normally distributed data and p<0.05 was considered statistically significant.
Tables and graphics were constructed using Microsoft Excel (2008). Adobe Photoshop
2020 was used for ensemble figures, keeping the original images in the proper resolution.

Results
Hyperoxia induces a decrease in Bmi1 protein levels in wild-type mice.
FVB wild-type mice were exposed to normoxia or hyperoxia conditions to
determine Bmi1 expression. Bmi1 protein expression decreased significantly after 48h of
hyperoxia exposure in wild-type mice as shown by western blot analysis on lung protein
extracts (Figure 3.2). Due to this finding, I wanted to determine whether Bmi1 was
necessary to respond to HALI.

Changes in protein expression in Bmi1־/‐ mice.
The expression of several proteins was evaluated in lung protein extracts isolated
from WT and Bmi1־/‐ mice after NO and HO exposure (Figure 3.2 A & B). Mitochondrial
fusion (mitofusin and OPA1) and fission (DRP1) protein expression were determined to
establish the effect of Bmi1 depletion.
Fission protein DRP1 (dynamin like-1 protein) expression in Bmi1-/- mice exposed
to NO or HO and in WT mice exposed to HO was significantly decreased. Of the proteins
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analyzed by western blot, only DRP1 showed an additive effect between the injury caused
by hyperoxia and the deletion of Bmi1 (Table 3.1). There were significant differences
between WT and Bmi1-/- mice in Mitofusin1 and OPA1 (mitochondrial dynamin-like
GTPase) fusion protein expression under HO but not in NO. Pink1, Parkin and pAKT
(Ser473) protein expression levels were affected by HO but not by the deletion of Bmi1
protein.
Although the expression of PGC-1α (transcriptional coactivator peroxisome
proliferator-activated receptor-coactivator 1α) was not evaluated in this study, we
hypothesized that high levels of pAKT in our in vivo and in vitro experiments after
hyperoxia exposure could induce the inhibition of PGC-1α expression as has been
previously described (206, 207) . PGC-1α is a protein involved in regulation of
mitochondrial biogenesis and energy metabolism. This could be one of the pathways by
which mitochondrial function is regulated downstream of the suppression or deletion of
BMI1 expression (in vivo and in vitro). It was previously reported that BMI1
phosphorylation was mediated by AKT in human tumors (208). However, it would be
important to elucidate the interaction between BMI1 decreased o deleted expression and
pAKT and their impact in a HALI model.
Our findings demonstrated that protein expression for tumor suppressor PTEN was
influenced by the deletion of Bmi1 in the same way observed in epithelial lung cells after
BMI1 silencing. Protein expression comparisons between genotypes and oxygen
exposure are shown in Figure 3.2 B and the multivariate analysis is shown in Table 3.1).
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A

B

Figure 3.2. Mitochondrial dynamics and function: Protein expression in wild-type and Bmi1־/‐ mice.
A. Western blot for mitochondrial dynamics and mitochondrial regulation proteins in WT and KO mice lung
tissue after exposure to NO and HO conditions. B. densitometric analysis of western blot normalized to βactin. N=6, mean +/- SEM; * p-value ≤0.05, ** p-value ≤0.01, ***p-value≤0.001. The absence of asterisks
indicates the lack of significant statistical differences.
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Table 3.1. Summary of P-values of two-way MANOVA for protein expression levels in wild-type and
Bmi1 knockout mice.
Dependent variable
Independent variable
DRP1

OPA

MFN1

Pink1

Parkin

pAKT

AKT

PTEN

O2 Concentration

0.044

0.276

0.705

0.017

0.008

0.025

0.204

0.680

Genotype

0.002

0.518

0.203

0.086

0.056

0.661

0.927

0.011

O2* Genotype

0.002

0.726

0.105

0.110

0.182

0.604

0.745

0.836

Bmi1 deletion confirmed by quantitative RT-PCR
The mice used in this study were housed in the Morsani College of Medicine
Comparative medicine facility and tissue samples were sent to TransnetYX ®, Inc for
genotyping. Bmi1 gene transcript levels were corroborated at the beginning of the study
using TaqMan RT-qPCR probes Bmi1 (Mm00776122_gH), β-Actin (Mm02619580_g1)
evidencing the absence of the transcript in Bmi1־/‐ mice (Figure 3.3)

ns
p=0.057123

Relative Fold Changes
against β-actin

1.6
1.4
1.2
1

0.8
0.6
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p=0.007776
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p=0.007744

0.4
0.2
0

WT NO

Bmi1 ‐/ NO

WT HO

Bmi1 ‐/ HO

Figure 3.3. Relative fold change of Bmi1 transcript compared with β-Actin in WT and Bmi1־/‐ mice
n=3 (mean+/-SEM), simple comparisons between oxygen concentration (normoxia and hyperoxia) and
genotype (WT and Bmi1־/‐), ns=not significant, * * p-value ≤0.01
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Figure 3.4. Oxygen Consumption Rate. A. Live mitochondrial respiration, OCR is higher in live
mitochondria isolated from lungs of WT mice in NO than in the other animals evaluated evidencing the
deleterious effect of hyperoxia exposure. B. Basal respiration, C. Proton leak, D. ATP production, E.
Spare respiratory capacity; all the parameters were expressed in pmol/min/ug-protein. Mean +/- SEM; *pvalue ≤0.05, ** p-value ≤0.01, ***p-value≤0.001.
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BMI1 depletion interferes with mitochondrial respiration.
Oxygen consumption rate (OCR) experiments were performed on live
mitochondria isolated from pulmonary tissue as described previously, to establish if Bmi1
depletion interferes with mitochondrial function. In general, respiratory parameter values
were highest for mitochondrial derived from WT mice under normoxia (Figure 3.4 A, B).
For animals exposed to normoxic conditions, the basal respiration was approximately 3.0
pmol/min/ug protein and was less than 1.0 pmol/min/ug protein for mice exposed to
hyperoxic conditions. The same trend was observed in ATP production which was
decreased by hyperoxia injury in both genotypes (WT and KO, Figure 3.4 D). The proton
leak and spare respiratory capacity were affected by both the hyperoxia-induced injury
and by the genotype (Figure 3.4 C, E). The oxygen consumption was significantly higher
in mitochondria isolated from the lungs of WT mice in normoxic conditions than in
mitochondria isolated from the same genotype under hyperoxia or derived from Bmi1 KO
mice (under NO or HO), turned to the quiescent phenotype (Figure 3.4 A).

Bmi1 depletion and hyperoxia did not promote significant changes in
tricarboxylic acid cycle (TCA) enzyme activity.
Mitochondria from the lungs of WT and Bmi1־/‐ mice were isolated after NO or HO
exposure to determine mitochondrial functionality by measuring, fumarase, aconitase
and citrate synthase activity. There were statistically significant differences associated
with genotype for aconitase activity. However, there were no significant changes in
fumarase, and citrate synthase activity associated with hyperoxia exposure or Bmi1. 1.
Fumarase activity was approximately 0.00032 milliunits/ul for all the animals evaluated
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(Figure 3.5 A). 2. Aconitase activity showed significant differences associated with
increased enzymatic activity in mitochondria isolated from Bmi1 depleted mice
compared to wild-type mice (Figure 3.5 B). 3. There were no significant differences in
citrate synthase activity between the groups. However, citrate synthase activity
increased in WT mice and decreased in Bmi1 KO mice after HO, compared to the same
genetic background in normoxic conditions. (Figure 3.5 C). These enzymatic assays
showed that fumarase and citrate synthase activity in mitochondria derived from lung
tissue are not significantly affected by hyperoxia or Bmi1 depletion.

Bmi1 genetic deletion exacerbates structural damage in hyperoxia-induced
acute lung injury.
To determine the relevance of Bmi1 genetic deletion in lung structure, isolated
lungs from WT and Bmi1-/- mice exposed to NO and HO were formalin fixed, paraffin
embedded (FFPE) and sectioned. Hematoxylin and eosin (H&E) histological staining was
completed, and stained sections were examined by light microscopy to determine the
acute lung injury score (ALIS). Lungs from WT mice exposed to 48h of hyperoxia showed
mild to moderate damage (ALIS = 1.92) with increased alveolar edema, thickness of the
alveolar wall and infiltrating immune cells (Table 3.2).
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Bmi1-/- mice under NO conditions had moderate damage with an ALIS <2, while
mice with the same genetic background exposed to 48h of HO presented with severe

A

Fumarase activity
(nmol/min/uL)

damage involving 50-75% of the evaluated area (Table 3.2 and Figure 3.6).

0.00035
0.00032
0.00029
0.00026
Bmi1 ‐/ NO

B

Aconitase activity
(nmol/min/mL)

WT NO

WT HO

Bmi1 ‐/ HO
*
*

*

5.4
5.2
5.0
4.8
4.6
4.4
WT NO

Bmi1 ‐/ NO

WT HO

Bmi1 ‐/ HO

WT NO

Bmi1 ‐/ NO

WT HO

Bmi1 ‐/ HO

Citrate Synthase
Activity (nmol/min/uL)

C
0.0008
0.0006
0.0004
0.0002
0

Figure 3.5. Mitochondria Activity Assays. A Fumarase (nmol/min/uL): no significant decrease in activity
after HO in WT and Bmi1-/- mice. B Aconitase (nmol/min/mL): significant reduction in activity in Bmi1־/‐ in
normoxia and hyperoxia. C Citrate synthase (nmol/min/uL): no significant difference between groups, n=3,
mean +/- SEM; two-ways MANOVA *p-value ≤0.05.
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Table 3.2 Acute lung injury score (ALIS)
Peribronchiolar

Immune Cell

Interstitial

Alveolar

Infiltration

Hemorrhage

Infiltration

Thickening

Edema

Wild-type Normoxia

0.4667

0.0667

0.2000

0.6667

0.2667

Bmi1 ־/‐ Normoxia

1.8000

1.2000

2.2000

2.0000

1.7333

Wild-type Hyperoxia

1.4667

1.7333

2.6000

2.0000

1.8000

Bmi1 ־/‐ Hyperoxia

2.9333

2.6000

3.0667

2.9333

2.7333

*

Acute Lung Injury Score (ALIS)

*

3.5
**

*

3.0
2.5
2.0

**

***

KO NO

WT HO

1.5
1.0
0.5
0.0
WT NO

KO HO

Figure 3.6 Acute lung injury score in wild-type and Bmi1־/‐ mice exposed to normoxic and hyperoxic
conditions. Acute lung injury parameters were evaluated in 5 independent fields with 3 mice per group,
bars show mean +/- SEM, * p-value ≤0.05, ** p-value ≤0.01, ***p-value ≤0.001.

The analysis of histological images to evaluate lung damage showed a deleterious
effect caused by the genetic deletion of Bmi1. Although it is known that hyperoxia induces
lung damage (HALI) as demonstrated in wild-type mice exposed to hyperoxia, this
damage was even more marked in Bmi1-/- mice (Figure 3.7).
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Figure 3.7 Bmi1 genomic deletion exacerbates HALI. Photomicrographs representative of H&E staining
for wild-type and Bmi1־/‐ mice exposed to normoxia and hyperoxia, magnification: 20× and 40×. Acute lung
injury parameters were evaluated in 5 independent fields with 3 mice per group. Bmi1־/‐ mice were more
susceptible to the injury caused by hyperoxia as evidenced by a loss of normal alveolar architecture and
an increase in the signs of damage. Black arrows show macrophages, green arrowheads indicate infiltrating
immune cells, H in red represents hemorrhage areas, IT (clear blue) shows interstitial thickening, *
designates alveolar edema and yellow stars are in regions with peribronchial infiltrates. Squares in 20×
magnification denote the region magnified at 40×.
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Lung injury determined by immune cell infiltration and alveolar
permeability is increased in Bmi1-/- mice exposed to hyperoxia.
Blood cellular migration and increased lung permeability are clues and
characteristic events in ALI. To identify if BMI1 had a role in HALI, and to determine the
effect of Bmi1 deletion on alveolar permeability and cell infiltration, 9 weeks old Bmi1 -/mice and their wild-type littermates were exposed to normoxia and hyperoxia for 48h.
BALF was collected, the number of infiltrating cells was counted and protein concentration
was measured; the alveolar permeability to Evans blue dye (EBD) was determined as
described previously.
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Figure 3.8 Bmi1 deletion increased permeability and immune cell infiltration after 48h of hyperoxia.
A. Bmi1-/-mice had increased immune cell numbers in BALF, and the cell number was significantly higher
after 48h of hyperoxia. B. Protein concentration in BALF was measured using BCA protein assay showing
the higher concentration for Bmi1-/-mice after HO. C. Alveolar permeability measured by EBD in BALF,
denoting increased absorbance in Bmi1-/-mice exposed to HO. D. Comparison of lungs extracted from mice
exposed to hyperoxia; lungs from Bmi1-/- mice are more bluish than lungs from WT animals. Data
represented, mean +/- SEM; for n=6, * p-value ≤0.05, ** p-value ≤0.01, ***p-value ≤0.001.
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Performed experiments demonstrated that Bmi1 deletion increases the infiltration
of immune cells in BALF, and cell migration is significantly higher after 48h of hyperoxia
(p<0.001). Protein concentration in BALF was twice higher for Bmi1 -/- mice exposed to
hyperoxia (0.27ug/ul) than the protein measured in WT mice in normoxia (0.14ug/ul).
Alveolar permeability increased in Bmi1-/- mice were evidenced by the extravasation of
Evans blue dye into the alveolar space and collected in the BALF, EBD permeability was
measured by absorbance at 630nm, denoting significant values in the mice exposed to
hyperoxia (WT and KO) being Bmi1-/- mice who had the highest value (Figure 3.8).
Determination of immune cell migration into the BALF was complemented with Diff
Quick staining which confirmed a significant polymorphonuclear cell migration,
accumulation of lymphocytes and increase of macrophages (Figure 3.9).

Bmi1 ־/- HO

WT HO

Figure 3.9. Increased immune cells were present in BALF from Bmi1 -/- mice compared to their wildtype littermates after hyperoxia. Diff quick staining for cells in BALF showed a higher number of
neutrophils (black arrows), individual lymphocytes (green arrowheads) and clumps were also found, and a
higher number of macrophages.
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Bmi1 depletion has a deleterious effect on lung function.
Spirometry is the most commonly performed lung function test in humans. In
animal studies exist a similar way to evaluate lung functionality. FlexiVent is the gold
standard technic to assess lung function in vivo models and has a high reproducibility
and efficacy. To determine is Bmi1 depletion was related with lung functionality in HALI,
a flexiVent analysis was performed for WT and Bmi1-/- mice after normoxia or hyperoxia
exposure.
The functional analysis showed that Bmi1 knockout mice had decreased
inspiratory capacity (IC) and compliance (Cst) compared with wild-type mice group. The
decrease was more significant in Bmi1-/- mice exposed to hyperoxia. Elastance (Ers)
and resistance (Rrs) increased in knockout mice versus their WT littermates. These
findings indicated that Bmi1 is necessary for adequate lung function and that hyperoxia
added to the lack of BMI1 exacerbates pulmonary dysfunction (Figure 3.10).

Discussion
Hyperoxia causes cell death, inflammation, mitochondrial dysfunction, and DNA
fragmentation at the molecular level, at a macro level induces changes in lung structure
and functionality (68, 70, 71, 73, 203). The second chapter of this dissertation mentioned
how diminished expression of BMI1 is associated with mitochondrial alterations, poor cell
survival and dysregulation of cell cycle (133, 209). This study provides evidence in vivo
that BMI1 is related to ALI/ARDS for the time. Using hyperoxia as a model to approach
ALI/ARDs in vivo permits to evaluate the molecular mechanism of the disease and
facilitates the understanding of this nosological entity that is not yet well understood.
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Figure 3.10. Bmi1 depletion has a deleterious effect on lung function. Elastance, resistance and tissue
damping increased in Bmi1 KO mice versus WT mice. Compliance and Inspiratory capacity decreased in
depleted mice and Newtonian resistance did not have significant changes between the mice under
normoxic conditions but increased in Bmi1 Ko mice under hyperoxia.
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Bmi1 depletion was correlated with decreased expression of Drp1 protein (Table
3.1). Kosmider and colleagues (2019) found impaired mitochondrial dysfunction
associated with the decrease of DRP1 protein in human epithelial cells in pulmonary
emphysema. Despite a balance is necessary between mitochondrial fusion and fission
the reduction of DRP1 in AECII contributes to cell death (161). In this study, we did not
investigate the subjacent mechanism by which mouse lung cells are affected downstream
of Drp1 decrease. Still, the relationship between Bmi1 genetic deletion and decreased
Drp1 levels was evident, and it can be explained in part by the mitochondrial alterations
observed in our model. It is important to emphasize that changes in protein expression
may differ between cell line or primary cell cultures (in vitro model) and proteins obtained
from tissues due to the multicellularity and complexity of the latter (in vivo model) (210).
Banerjee and colleagues (2016) described BMI1 localization inside of
mitochondria in the inner mitochondrial membrane in ovarian cell lines despite the lack of
a canonical mitochondrial targeting signal in the BMI1 sequence (160). Other noncanonical pathways have been described for protein transport through one or both
mitochondrial membranes (114, 211), however, this study did not track whether BMI1 was
located within the mitochondria in wild-type mice or in H441 cells. The location could be
determined to establish if the impact of BMI1 depletion or deletion in mitochondria is
direct, indirect or both.
PTEN tumor suppressor protein levels were significantly increased in Bmi1־/‐ mice
(as found in H441 cells silenced for BMI1), indicating that PTEN protein expression is
dependently regulated by Bmi1 expression (139, 167). The downstream PTEN activation
signaling pathway in lung tissue could be explained as described in the second chapter
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of this dissertation for human lung epithelial cells. The expression of PTEN is enriched by
the suppression of Bmi1, which in turn triggers an increase in pAKT (Ser 473) protein;
high levels of pAKT could inhibit PGC-1α (as mentioned in our in vitro model) which in
turn partially would explain changes in mitochondrial metabolism (206, 207). The
combination of Bmi1 decrease and PTEN and pAKT increase, inhibits the Akt/PKB
pathway that interferes with cell cycle and turnover, confirming the crucial role of BMI1 in
cell survival (167, 169).
The Bcl2 signaling pathway was previously demonstrated to be involved in
mitochondrial permeability; overexpression of Bcl2 confers a protective effect against
HALI (73, 212). We did not evaluate the protein expression of Bcl2 in this study, but we
found that after in vitro silencing of BMI1 or after hyperoxia exposure, Bcl2 transcript
decreased significantly. Kushwaha and collaborators (2020), found that for acute myeloid
leukemia (in vivo and in vitro), the downregulation of BMI1 inhibition of Bcl2 could explain
other indirect causes of mitochondrial dysfunction downstream of Bmi1 deletion or
depletion (213, 214).
Determination of oxygen consumption rate in live mitochondria is still a challenge
due to the limited time between organ collection and live mitochondria isolation (within 6
hours of euthanasia). We observed a decrease in the respiratory rate of the mitochondria
isolated from the genetically modified mice (Bmi1-/-) and WT hyperoxia mice using the
Seahorse Agilent analyzer. These changes were associated with decreased in ATP
production and spare respiratory capacity; similar findings were described previously for
mouse lung epithelial cells (Figure 3. 4) (177).
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Tricarboxylic acid cycle enzymatic activity was evaluated by measuring fumarase,
citrate synthase and aconitase activity. Aconitase activity was augmented in Bmi1-/- mice;
increased aconitase activity indicates a high energetic demand and the need for the cell
to produce more ATP to supply metabolic requirements and decrease inflammatory
response (215). However, cellular homeostasis is regulated in different ways, beyond the
activity of a single enzyme; in cardiac cells derived from mice, mitochondrial aconitase
activity increase has been related to enhanced oxidative injury (216).
Hallmarks of ALI/ARDS include the migration of polymorphonuclear blood cells
into alveolar space, cytokine storm, alveolar-capillary barrier dysfunction with an increase
in lung permeability, mitochondrial damage, and increased oxidative stress. Mice with
different genetic backgrounds have been studied in Dr. Kolliputi’s laboratory to assess
the molecular basis of HALI (156, 159, 203, 217); this research approach has identified
several risks and protective factors for HALI and the disease has been examined not only
with molecular markers but with the direct evaluation of lung injury (histology) and function
(flexiVent).
Acute lung injury score (ALIS) is used to establish the level of damage in lung
architecture, and it is directly related to the injury severity (194, 196). ALIS analyzed in
our studies corroborates the hypothesis of this study, demonstrating that decreased Bmi1
expression worsens HALI (Figures 3.6 and 3.7, Table 3.2). ALIS in Bmi1־/‐ mice exposed
to hyperoxia showed a severe disease state with increased alveolar wall thickness,
hemorrhage, disruption of the alveolar-capillary barrier leading to increased lung
permeability (analysis of BALF protein levels, BALF cellularity, and EBD extravasation),

90

increased infiltration of immune cells (PMN, lymphocytes, and macrophages) and
pulmonary edema (Figures 3.8 and 3.9).
Data from lung function analysis in vivo (flexiVent) showed that adequate Bmi1
expression is necessary to maintain lung compliance and the ability of lung tissue to
expand and stretch as needed (it is closely related to lung elastance). Bmi1 deletion was
associated with the loss of compliance and limited inspiratory capacity. In addition, there
is an increase of the lung resistance to the adequate distensibility, worsening the
symptoms of the disease as is present in patients with ALI/ARDS. Our results showed
that these four features of lung function (compliance, inspiratory capacity, resistance and
elastance) were more drastically affected in Bmi1-/- mice exposed to hyperoxia compared
to wild-type mice or Bmi1-/- mice under normoxic conditions, evidencing that Bmi1 loss
has a deleterious impact on the response to hyperoxia injury (Figure 3.10) (204).

Summary
This study shows the decrease of BMI1 expression as a possible cause of
ALI/ARDS. The deletion of Bmi1 was related to a fast and severe establishment of HALI;
we observed a decrease in lung function parameters and an increase in lung permeability,
and cellular and protein extravasation, evidencing the importance of this protein to
response to the injury caused by hyperoxia.
Our animal model experimental results showed BMI1 as a candidate molecule in
the study of HALI, and future evaluation could be helpful in the management of this
complex nosological entity.
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Limitations of in vivo model and Future Directions
We used a whole-body Bmi1 knock-out mouse model. These animals have a
phenotype with hematopoietic abnormalities, neuronal deficit, growth and development
alterations, poor survival and early death. These characteristics made it difficult to have
more significant sample number for to analyze all the evaluated parameters. We suggest
further studies using conditional knockout mice lacking lung Bmi1 expression to assess
HALI.
Future studies to determine the impact of tissue-specific Bmi1 knock-out
expression could be completed by breeding the conditional knock-out for Bmi1 with the
mito-QC Reporter Mouse as described by McWilliams and collaborators in their PINK1
study (218, 219). This in vivo model will verify the impact of knocking out Bmi1 expression
and also allow the evaluation of mitophagy.

We suggest experiments to verify if Bmi1 expression confers a protective effect
against HALI, inducing the recovery of Bmi1 expression (in Bmi1 conditional or Bmi1
whole-body knockout mouse models) using adenoviruses or lentiviruses as described by
Kim et al. (2021), in Alzheimer disease (220). After Bmi1 recovery is achieved, we
recommend to evaluate proteins expression, mitochondrial function and lung function.
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Chapter 4: Clinical relevance of BMI1 expression in samples from patients
with ALI/ARDS

Background
The study of acute respiratory distress syndrome (ARDS) and its mild
presentation, acute lung injury (ALI), has been fundamental in the advancement of
pulmonology due to the mortality and morbidity of the disease. The SARS-Cov-2
(COVID-19) virus pandemic has created more interest in a deeper understanding of this
disease. The association of SARS-Cov-2 infection with the development of ARDS
(COVID-19- associated acute respiratory distress syndrome (CARDS)) (221) has
necessitated thorough and rapid investigation towards therapeutic management.
Individuals with CARDS have a mortality rate of 30-50% vs 3% in COVID-19 patients
who do not develop ARDS. However, despite the increased number of ARDS studies,
the molecular mechanisms of disease development remain unknown.
In this study, it was demonstrated in vitro and in vivo that the decrease or
depletion in the expression of BMI1 is related to the onset of the disease. To determine
if these results could be extrapolated to humans, postmortem lung tissue sections and
biopsies of transplanted lungs from individuals with various lung diseases were
analyzed for BMI1 protein expression.
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Materials and Methods
We analyzed human lung tissue from six groups: 1. Non-smokers (had healthy
lungs and no history of smoking and used as control group (n=10); 2. Smokers (had a
history of smoking with no other known lung diseases), (n=9); 3. ARDS patients, (n=9);
4. Chronic obstructive pulmonary disease (COPD) patients, (n=9); 5. Idiopathic
pulmonary fibrosis (IPF) patients, (n=8); 6 interstitial lung disease (ILD) patients, (n=10).
Lung tissues were provided by Dr Karim Bahmed and Dr Beata Kosmider from the
Center for Inflammation and Lung Research, Temple University, Philadelphia, PA and
Dr. Nirmal Sharma, Tampa General Hospital, Tampa, FL.
Lung tissue samples were frozen in liquid nitrogen followed by pulverization and
isolation as previously described for mouse lungs (in Chapter 3). Briefly, tissue was
homogenized in lysis buffer containing 150 mM NaCl, 50 mM Tris, and 0.5% NP40, pH
7.4 supplemented with protease and phosphatase inhibitors 1:100, followed by
sonication, centrifugation, and collection of supernatants. The total protein concentration
was determined using the BCA protein assay (ThermoFisher Scientific, Inc #23225,
Pierce, Rockford, Waltham, MA).

Western Blot Analysis
For protein separation, human lung lysates (10 µg) were loaded onto 4-20%
gradient SDS-PAGE. Following gel electrophoresis, the proteins were transferred to
PVDF membrane, blocked in 5% BSA in TBST, and incubated with BMI1 primary antibody
overnight at 4°C. After TBST washes, a secondary goat anti-rabbit HRP-conjugated
antibody was added. The membrane was incubated for 1 hour at room temperature,
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followed by TBST washes and protein visualization with ECL as previously described (in
Chapter 2). BMI1 protein expression was quantified using the ImageJ (NIH, Bethesda,
MD) image processing program and normalized to β-actin (antibodies and conditions are
listed in Appendix 2).

Statistical Analysis
Age and gender for the non-smoker and ARDS groups are represented as mean
+/- SEM (standard error of the mean); the data were analyzed by two-tailed unpaired
student’s t-test using GraphPad Prism version 10 and IBM SPSS Statistics v26. The
visualized proteins were quantified by ImageJ (NIH, Bethesda, MD), and the ratio of
protein to its loading control (β-actin) was calculated using the ImageJ software. Data
were analyzed using ANOVA and Tukey’s posthoc test for normally distributed data, and
p<0.05 was considered statistically significant. Results were graphed using Microsoft
Excel (2008). Adobe Photoshop 2020 was used for ensemble figures, keeping the original
images adequately.

Results
Demographic information
Age and gender demographic data were obtained for the non-smoker and ARDS groups
(Temple University). In the non-smoker group, 50% were women, and 50% were men.
In the ARDS group, 57% were males, and 43% were women. There were no significant
differences in gender distribution between these two groups. The average age of death
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in each group was 58.5 years (non-smokers) and 37 years (ARDS) with significant
differences in the age of death being lower in the ARDS group (Figure 4.1).

Figure 4.1. Distribution of age of death for human lung samples in non-smokers and ARDS groups.
Non-smokers group (Max. 82 years, Min 22 years, Mean 58.6 years). ARDS group (Max. 68 years, Min. 12
years, Mean 37 years).

BMI1 expression is decreased lung tissue from ARDS patients
A total of 9 ARDS samples were analyzed to determine BMI1 protein expression.
A decreased expression of BMI1 protein was found in ARDS lung tissue versus the nonsmoker lung tissue (p=0.04412) (Figure 4.2). There were no statistically significant
differences in BMI1 expression between any other groups and the control group (nonsmokers). The highest mean expression of BMI1 protein was observed in the IPF and
smoker groups (Figure 4.2).
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Figure 4.2 BMI1 protein expression in human lungs with different pathologies. A. Western blot for
BMI1 and β-actin expression. B. Graphic of BMI1 expression normalized to β-actin (samples, where β-actin
was below the detection limit, were omitted from the statistical analysis). Bars represent mean +/- SEM.
Non-smokers and ILD n=10, smokers, ARDS, COPD n=9, IPF n=8. The non-smoker group was used as
control. Smokers and IPF groups showed the highest BMI1 expression, ARDS was the only group with
significantly decreased expression p=0.04412. ARDS: acute respiratory distress syndrome, COPD: chronic
obstructive pulmonary disease, IPF: idiopathic pulmonary fibrosis, ILD: interstitial lung disease.

Discussion
BMI1 plays a crucial role in cell survival and renewal; maintenance of its normal
expression is related to control of ROS production, regulation of DNA damage response
pathway, and cell cycle control (133, 134, 160). The study of BMI1 function in the lung
has been limited to research in cancer and to elucidate whether upregulation or
downregulation affects the severity of lung cancer or lung tumorigenesis (222-227).
This analysis shows the importance of studying the role of BMI1 outside the
carcinogenic context in the lung. Decreased BMI1 expression was demonstrated for
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ALI/ARDS in our in vivo and in vitro models; the preliminary results in human lung tissue
showed similar decreased BMI1 protein expression in ARDS patients.
Our current results cannot prove an absolute correlation between decreased BMI1
expression and ARDS; however, our preliminary results showed a significant downward
trend. Due to the source and the sample size evaluated in this study, we could not
determine several factors that could regulate the expression of BMI1 in ARDS. These
factors for the development of ARDS, etiology, age of presentation, gender, were
described in chapter 1 of this dissertation. It is known that males are more likely to suffer
ARDS than females (228), but we could not observe those differences in this study, due
to the sample size.
We found significant differences in the age of death between the non-smoker and
ARDS groups; the patients with ARDS, on average, died 21 years earlier than nonsmokers. (The information collected from Temple University was that the cause of death
for ARDS patients was the disease itself, while we were not provided with the cause of
death for patients in the non-smoker group). ARDS can be observed at any age, but the
incidence increases with age, like the death rate. However, the mean age of death in our
group was lower than previously observed in patients from Spain, Taiwan, and the USA,
probably due to sampling size (228-233).
Reynolds and collaborators (2019), found that ARDS has a lower incidence in
patients older than eighty years, but in older patients (>80 years) the mortality is double
that as compared to younger patients (<80 years) (233); they suggest that the low
incidence could be due to underdiagnosis, decrease in the inflammatory response, or
comorbidities that mask the disease.
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Schouten and colleagues (2019) suggest that age-related differences in ARDS
could be mediated by the increase of pulmonary inflammatory mediators (cytokines and
chemokines), the expression or activation of biomarkers involved in immune response
(signaling molecules such as ICAM-1), and neutrophil migration and activation.

Limitations and Future Directions
We hypothesized that BMI1 expression would be decreased in lung tissue from
ARDS patients compared to healthy patients. Our preliminary results show decreased
lung BMI1 protein expression in ARDS patients, and they showed a significant difference
between these patients and the non-smoker controls. However, to definitively state that
decreased lung BMI1 expression is present in ALI/ARDS the following will be required: 1.
Increase the sample size of ARDS and control patients, 2. Complete a systematic
sampling in postmortem or transplanted lungs from the different pulmonary lobes and
from regions where the lung tissue damage is visible at a microscopic level vs. areas not
affected by the disease, 3. Obtain samples from across the age spectrum to increase the
database and to collect more epidemiological data (race, gender, age, risk factors,
etiology, and associated comorbidities).
The lung tissue should be collected as soon as possible postmortem or from
posttransplant patients and processed immediately to perform different molecular studies
such as enzymatic activity and mitochondrial function.
More studies are necessary to confirm that our findings in human lung tissue are
reliable; however, the preliminary results here frame an important study topic for ARDS
research. The metabolic pathway downstream of BMI1 decreased expression and its role
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in ARDS is still not clear. Future directions to answer the hypothesis proposed here, are
experiments where BMI1 decreased expression induces PTEN overexpression,
mitophagy, alterations in PI3K/AKT pathway, and changes in TCA cycle enzyme activity
could be tested in lung tissues collected from patients with ALI/ARDS.
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Chapter 5 Conclusions

Our in vitro model showed that BMI1 silencing has a deleterious and additive effect
that exacerbates HALI by inducing more mitochondrial damage and dysfunction, not only
in terms of protein activation but also in the cellular and mitochondrial capacity for energy
production, metabolism (TCA cycle), production of ROS, and oxidative stress response.
While we did not elucidate the mechanism by which BMI1 silencing worsens
mitochondrial damage caused by hyperoxia, we showed changes in DRP1, PTEN,
Parkin, and pAKT protein levels that could be related to the observed mitochondrial
dysfunction.
Bmi1 deletion was related to the severity of lung damage caused by hyperoxia in
vivo as was evidenced at the micro-level by changes in mitochondrial dynamic marker
protein expression and decreased mitochondrial OCR, and at the macro-level by the
increase in lung permeability, protein extravasation and cellularity in BALF and by
deleterious changes in lung function; all of these hallmarks have been seen in human
patients with ALI/ARDS.
BMI1 association with ALI/ARDS development and severity in our in vitro and in
vivo models shows the relevance of continuing the study to establish if BMI1 affects
mitochondrial function directly or indirectly in ALI/ARDS. If our hypothesis and future
directions could be addressed, it will be possible to determine if BMI1 is a therapeutic
target for disease management.
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Based on our findings, we would like to propose a model to outline a possible
pathway to induce mitophagy downstream of BMI1 silencing or deletion in normoxia and
hyperoxia conditions (Figure 5.1).

Basal conditions

Hyperoxia

BMI1 silencing

BMI1 silencing + Hyperoxia

Figure 5.1. Proposed pathway downstream of BMI1 silencing in hyperoxia conditions. Top left
panel: Basal conditions (normoxia and non-silenced BMI1). Top right panel: Hyperoxia conditions
(oxygen concentration>80% and non-silenced BMI1). Bottom left panel: Normoxia and silenced BMI1.
Impact of BMI1 silencing in normoxia. Bottom right panel: Hyperoxia and silenced BMI1. Effects of BMI1
silencing in hyperoxia.

We suggest this signaling pathway as a way to target BMI1 in ALI/ARDS: 1.
Recover the expression of BMI1 to avoid oxidative stress and mitochondrial dysfunction
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in lung epithelial cells and 2. Use the mitochondria as a therapeutic target to treat the
disease (mitochondrial transplant or treatments) and improve mitochondrial function and
generation.
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Appendix 2. Table of antibodies
Table A1. Antibodies and conditions of western blot

Antibody Name

Type

Solution

Incubation

MW (kDa)

Secondary

Rabbit

Primary
Concentration
1:1000

AKT
p-AKT (Ser 473)
ALDH2
β-Actin
β-Actin
BMI1
DJ1
DRP1
Mitofusin 1

Secondary
Concentration
1:5000

Company

Reference

5% BSA

ON

60

Goat anti Rb

Rabbit
Rabbit
Rabbit
Mouse
Rabbit
Rabbit
Rabbit
Mouse

1:1000
1:100-1:500
1:5000
1:5000
1:1000
1:1000
1:1000
1:1000

5% BSA
5% Skim Milk
5% BSA
5% BSA
5% BSA
5% BSA
5% BSA
5% BSA

ON
ON
45 min
45 min
ON
ON
ON
ON

60
56
45
45
41-43
22
78-82
84

CST

#4691

Goat anti Rb
Goat anti Rb
Conjugated
Conjugated
Goat anti Rb
Goat anti Rb
Goat anti Rb
Goat anti Ms

1:5000
1:5000

1:5000
1:5000
1:5000
1:5000

CST
Abcam
CST
CST
CST
CST
CST
Abcam

#4060
Ab70917
#4970
#12262
#5856
#5933
#8570
ab 57602

Mitofusin 2
OPA1
Parkin

Rabbit
Rabbit
Mouse

1:1000
1:1000
1:1000

5% BSA
5% BSA
5% BSA

ON
ON
ON

80
86-111
50

Goat anti Rb
Goat anti Rb
Goat anti Ms

1:5000
1:5000
1:5000

CST
Novusbio
CST

#9482
NB110-55290
#4211

PINK1
PTEN

Rabbit
Rabbit

1:1000
1:1000

5% BSA
5% BSA

ON
ON

50-60
54

Goat anti Rb
Goat anti Rb

1:5000
1:5000

CST
CST

#6949
#9188

ON: Over Night. CST: Cell Signaling Technologies
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Appendix 3. Proteins of Inflammasome, DDR pathway and Adhesion

A

BMI1
β-actin
γH2AX
IFI 16
E-Cadherin

siRNA

Control

BMI1

NORMOXIA

Control

BMI1

HYPEROXIA

B

Figure A1. Expression levels of γH2AX, IFI16 and E-Cadherin proteins in Control and BMI1
silenced H441 Cells. A. Western blot for protein expression levels in normoxic and hyperoxic conditions
B. densitometric analysis of western blot normalized to β-actin. n=3, mean +/- SEM; * p-value ≤0.05, ** pvalue ≤0.01, ***p-value≤0.001.
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Appendix 4. BMI1 overexpression experiment

We overexpressed BMI1 and then performed silencing experiment. In that
experiment, we used different treatment combinations as is shown in the table A3 and
western blot images are shown in figure A3 (blots 1-5).

Table A3. BMI1 overexpression conditions

Group
Number
1
2
3
4
5
6
7
8
9
10
11
12

Treatment
Control NO, Scramble siRNA ON, expose to NO 48h
BMI1 siRNA ON, expose to NO 48h
Control HO, Scramble siRNA ON, expose to HO 48h
BMI1 siRNA ON, expose to HO 48h
BMI1 OE ON, expose to 48h NO
BMI1 siRNA ON, expose to NO 48h BMI1 OE ON,48h NO
Endogenous BMI1, expose to 48h NO
BMI1 OE ON, expose to 48h HO
Endogenous BMI1, expose 48h HO, BMI1 OE ON, expose 48h NO
Endogenous BMI1, expose 48h HO, BMI1 OE ON, expose 48h NO,
expose 48h HO
BMI1 OE ON, expose 48h NO, BMI1 siRNA ON, expose to NO 48h
BMI1 OE ON, expose 48h HO, BMI1 siRNA ON, expose to HO 48h

Over Expression and silencing experiment.
Blot 1 shows the effect of non-silencing BMI1 expression using scrambled siRNA and
silenced BMI1 in H441 cells under normoxia and hyperoxia conditions (groups 1-4 from
the table) as explained in the paper the expression of BMi1 decreased with HO and
when HO is combined with silencing the expression is lower than silencing only using
siRNA.
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Blot 2 shows over expressed BMI1 in NO (group 5); in group 6 H441 cells were first
silenced and then we tried to over express BMI1. However, after silencing the
effectiveness of OE was less; the group 7 shows the basal expression of BMI1 without
any treatment; group 8 showed low endogenous and overexpressed BMI1 after HO,
showing deleterious effect of HO in BMI1 expression.
Blot 3 represents the results obtained after over expressing BMI1 followed by HO
induced reduced expression (comparison between groups 8,9 and10).
Blot 4 is a combination of endogenous and over expressed BMI1 treatments, group 9
showed the decreased endogenous BMI1 expression after HO but shows
overexpressed BMI1 indicating a possibility for recovering its expression (we will
evaluate the impact of BMI1 overexpression in future studies).
Blot 5 shows over expression followed by silencing of BMI1 under NO and HO
conditions (groups 11 and 12). NO= Normoxia, HO= Hyperoxia, OE= over expression,
ON= overnight, Endogenous= BMI1 expression without any treatment, OE BMI1
molecular weight = 68-70kDa (BMI1 41-43 kDa +GFP 27kDa)
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BLOT 1

BLOT 2

BLOT 3

BLOT 4

BLOT 5

Figure A3. BMI1 overexpression under different conditions of silencing and hyperoxia
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